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ABSTRACT
Obesity is characterized by an overabundance of fat cells, or adipocytes, and is currently
a global epidemic. Adipocytes store energy, respond to insulin, and participate in diverse
endocrine signaling pathways by secreting adipokines. Obesity leads to the dysregulation of
adipocyte function, which could lead to numerous metabolic diseases, such as Type II diabetes.
Understanding the mechanisms that regulate adipocyte development and involvement in
endocrine signaling will lead to a greater understanding of the importance of fat metabolism in
full-body health. Many lines of evidence demonstrate the importance of various transcription
factors in regulating adipogenic processes, and one of which is the Signal Transducer and
Activator of Transcription (STAT) proteins. Work by a variety of laboratories has demonstrated
that STAT proteins, particularly STAT5A, are activated and induced during adipogenesis and
play an important role in adipose tissue development.

Novel studies highlighted in this

dissertation demonstrate that pyruvate dehydrogenase kinase (PDK)-4, a known regulator of
glycolysis, is highly induced in adipocytes by growth hormone (GH) or prolactin (PRL) in a
STAT5 dependent manner. Under these conditions, the induction of PDK4 is accompanied by
insulin resistance. Because adipocytes also express other STATs, we observed the effects of
other STAT activators on adipocytes both in vitro and in vivo. Adipocytes are responsive to
gp130 cytokines, and these cytokines have diverse functions in adipocytes, as well as other
tissues. All gp130 cytokines share glycoprotein 130 as a common transducer protein in their
functional receptor complex and typically activate STAT3.

Several gp130 cytokines

differentially affect adipogenesis and insulin-stimulated glucose uptake, as well as crosstalk with
other members of the gp130 family to alter one another’s signaling. Novel studies highlighted in
these studies demonstrate that adipocytes both in vitro and in vivo are responsive to neuropoietin
viii

(NP), which can inhibit adipogenesis and negatively regulate insulin signaling. Importantly, NP
does not activate the LIF receptor, although previously reported to do so, and does not crosstalk
with other gp130 cytokines. An in-depth analysis of STATs, as well as their activators, will
enable us to understand how their role in adipocytes could contribute to the pathogenesis of
metabolic disease.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Adipocytes
Adipocytes are tightly packed cells that form and store fat in adipose tissue. They are
highly specialized in function and play a critical role in energy homeostasis in vertebrate
organisms (reviewed in (1)). The size and distribution of adipocyte stores in the body greatly
affect metabolism in human disease. Excessive growth in adipose tissue mass and adipocyte size
are hallmarks of obesity, which is the primary disease of fat cells.

Obesity modifies the

endocrine and metabolic functions of adipose tissue, which contribute to various metabolic
complications. Hence, obesity is a major risk factor for the development and/or progression of
many diseases; most notably non-insulin dependent diabetes mellitus (NIDDM) (2),
cardiovascular disease, and atherosclerosis (reviewed in (3)). Obesity is becoming increasingly
prevalent in the United States (4) and is strongly correlated with an increase in NIDDM, or type
2 diabetes mellitus (T2DM) (reviewed in (5)). Likewise, 80% of type 2 diabetics are overweight
or obese (reviewed in (6)). The study of adipose tissue, specifically adipocytes, is essential for
understanding the metabolic abnormalities associated with obesity.
One of the primary functions of adipose tissue is to synthesize and store excess energy as
triglycerides (TGs), or lipid, as well as to release it in the form of free fatty acids (FFAs) and
glycerol during fasting (reviewed in (1)). The mature adipocytes within the adipose tissue
expand as they take up lipid, and preadipocytes differentiate (adipogenesis) to become mature
adipocytes that are capable of additional fat uptake and storage. In addition to its role as an
energy reservoir, the adipose tissue also possesses other distinct properties: endocrine function
via the release of adipokines (cytokines or hormones synthesized and released by adipose tissue)
1

and sensitivity to insulin. The discovery that leptin, a satiety factor that regulates food intake and
energy metabolism, is an adipokine, was the first evidence of adipose tissue as an endocrine
organ (7). Since then, numerous other adipokines that exert diverse effects on metabolism have
been discovered (reviewed in (8)). These endocrine signals allow the adipocyte to regulate the
metabolism of not only other fat cells, but also cells that are located in numerous other tissues.
The fact that a subset of these adipokines- leptin (7), adiponectin (9), and resistin (10)- can only
be secreted from adipose tissue contributes to the importance of its endocrine function. Many of
these vital adipokines are involved in the metabolic disorders associated with obesity and insulin
resistance.
The regulation of glucose metabolism is essential for metabolic homeostasis, and insulin,
which enhances overall glucose disposal, is the dominant hormone that maintains this control.
Though most cells are responsive to insulin, in the fed state, insulin stimulates glucose uptake
into only two main target tissues: one of which is adipose tissue. Insulin resistance is the failure
of target tissues to respond to physiological levels of insulin (reviewed in (11)) and is a key
element in the pathogenesis of T2DM (12;13). This severe metabolic disorder often results in
hyperglycemia (excessive blood glucose levels) and can lead to major complications, including
neuropathy, nephropathy, and retinopathy.
In recent years, adipose tissue has been increasingly recognized for its active role in the
maintenance of glucose homeostasis, as well as whole-body metabolic homeostasis. This idea is
supported by studies demonstrating that a lack of or severe reduction in adipose tissue causes
insulin resistance in both mice (14) and humans, as in the case of lipodystrophy (15)(reviewed in
(16)).

Likewise, it is well known that excess adipose tissue is associated with decreased

sensitivity to insulin. Hence, normal glucose homeostasis is contingent upon functional adipose
2

tissue of a proper amount. An impaired capacity to properly store excess dietary fat intake due to
too much or too little adipose tissue may result in insulin resistance. The mechanisms linking
obesity, namely adipose tissue metabolism, to insulin resistance are intensely investigated, and
all involve the inability of adipocytes to function in their innate fashion. Taken together, these
findings suggest that adipose tissue dysfunction plays a vital role in the pathogenesis of obesityrelated T2DM.
Adipose tissue expansion through both increased adipocyte recruitment (hyperplasia)
and adipocyte enlargement (hypertrophy) is critical for the safe storage of lipid. An increasingly
popular hypothesis that correlates with insulin resistance is adipose tissue expandability, which
postulates that each individual’s adipose tissue may have a maximum capacity to efficiently store
fat (reviewed in (17)). Hence, an individual will remain metabolically healthy, even if they
become obese, as long as the adipose tissue can safely accommodate the excess caloric intake.
Any loss of capacity for storing fat can promote insulin resistance. When this maximum storage
capacity is reached, lipid spillage occurs, causing increased circulating levels of FFAs. Many
lines of evidence demonstrate a strong association of obesity and insulin resistance with high
circulating FFA levels (reviewed in (18)). Consequently, various non-adipose tissues, such as
skeletal muscle, liver, and the pancreas, accumulate excess ectopic lipid stores (lipotoxicity),
which may cause insulin resistance, as they lack the capacity to efficiently oxidize the excess
fatty acids (reviewed in (19)).

Several studies support the hypothesis of adipose tissue

expandability and its implications in disease. For example, studies in mouse models have
demonstrated that over expression of adiponectin in the ob/ob mouse caused an expansion of fat
mass, which led to an improvement in insulin sensitivity (20). In human subjects, studies have
shown that the PPARγ agonists, thiazolidinediones (TZDs), improve insulin sensitivity and
3

diabetes (21) and increase fat mass (22), supporting the idea that stimulating adipose tissue
expansion is associated with improved metabolism. In addition, several lines of evidence show
that individuals who are metabolically healthy but obese (MHO) have significantly increased fat
mass, but remain insulin sensitive and have no metabolic complications (23;24), presumably due
to the expansion of their adipose tissue. A better understanding of the mechanisms underlying
adipose tissue development, function, and expansion is required to improve the identification of
successful therapeutic approaches.
Studies also suggest that as adipocytes reach their maximum storage capacity, their
endocrine function is compromised, which yields derangements in adipokine secretion and
insulin resistance (reviewed in (25)). Human studies reveal a positive correlation between large,
lipid-filled adipocytes, insulin resistance, and altered adipokine secretion (26). In obese
individuals, the adipose tissue is engorged with TGs, and the adipocytes cannot efficiently store
additional lipid (reviewed in (19)). Therefore, the adipocytes become large and hypertrophied,
unresponsive to normal biological signals, and dysfunctional in the secretion of signaling factors.
Adipocyte size is linked to insulin sensitivity, for adipocyte hypertrophy is often observed in
obesity, as well as T2DM (27;28). Likewise, human studies demonstrated that weight loss
results in reduced adipocyte size (29).
It is well known that chronic, low-grade inflammation, characterized by abnormal
adipokine production, is positively correlated with obesity, insulin resistance, and T2DM.
Adipocyte hypertrophy stimulates the release of pro-inflammatory cytokines, which elicit this
effect (reviewed in (3)). Though the mechanisms underlying this inflammatory state have not
been fully elucidated, evidence suggests that macrophages, which are one of the numerous nonadipocyte cells located in the adipose tissue, contribute to the production of inflammatory factors
4

(reviewed in (19) and (30)).

Studies have shown that in obese individuals, hypertrophied

adipocytes synthesize and secrete large amounts of monocyte chemoattractant protein (MCP)-1
(31), which enhances macrophage infiltration into adipose tissue (32).

The additional

macrophage recruitment results in a chronic pro-inflammatory state stimulated by the release of
several cytokines, including tumor necrosis factor (TNF)α (33) and interleukin (IL)-6 (34). In
line with these findings, obese patients were shown to contain substantially more macrophages in
their adipose tissue than lean subjects (35), and obesity-related insulin resistance is correlated
with increased secretion of inflammatory cytokines (36).

Obese individuals also display

decreased levels of the insulin-sensitizing and anti-inflammatory factor adiponectin (37-39), as
well as significantly increased circulating levels of leptin, suggesting insensitivity to endogenous
leptin production (40). The inflammatory molecules have detrimental effects on adipose tissue
function, such as inhibition of both adipogenesis (41;42) and expression of important adipocyte
genes, including glucose transporter (GLUT)4, which is essential for insulin-regulated glucose
disposal (43). Both TNFα and IL-6 have been shown to increase lipolysis in adipocytes (44;45),
which may lead to increased levels of circulating FFAs and possibly insulin resistance.
Consequently, thiazolidinedione (TZD) treatment of obese rats stimulated an increase in the
number of small adipocytes and a decrease in the number of large adipocytes, causing
improvement of the adipokine signaling profile and normalization of increased levels of TNFα
(46). In turn, weight loss has been shown to cause decreased concentration of MCP-1 (47), as
well as a reduction in adipocyte hypertrophy and macrophage infiltration in adipose tissue
(48;49), which would collectively improve the inflammatory profile. Taken together, these
findings support the hypothesis that the inflammatory response contributes to dysfunctional
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metabolism in obesity via the altered release of adipokines, and this response may be mediated,
in part, by the infiltration of macrophages in adipose tissue.
1.2 The Transcriptional Control of Adipogenesis
Obesity and its related disorders result in dysregulation of the mechanisms that control
the expression of metabolic genes in adipocytes. Therefore, understanding adipocyte
differentiation is relevant not only for gaining insight into the pathogenesis of metabolic
diseases, but also for identifying proteins or pathways which might be appropriate targets for
pharmacological interventions.

In the last twenty years, significant advances towards an

understanding of the regulatory processes involved in adipocyte differentiation have largely been
made by the identification of several transcription factors that regulate the differentiation of fat
cells and/or are involved in the induction and maintenance of adipocyte gene expression.
Interestingly, the majority of studies that have identified transcriptional regulators of
adipogenesis have been performed in vitro. These studies have been primarily conducted in the
3T3-L1 or 3T3-F442A preadipocyte cell lines that were originally generated in the laboratory of
Dr. Howard Green at Harvard University (50;51). In the last thirty-two years, these cells lines
have been used by thousands of investigators world-wide. In vivo, adipocytes have three primary
characteristics, which include lipid storage, insulin sensitivity, and endocrine properties. The
3T3-L1 cells have all three of these notable characteristics of fat cells. In addition, many
adipocyte specific genes have been identified using this cell line. Many cell types cannot be
adequately studied in vitro because the cultured cells do not possess the properties of adipocytes
in vivo. However, the preadipocyte cell lines that were developed by Dr. Green have been an
extremely useful model system for adipocyte biologists, and the data obtained in these cells has
been validated from less mechanistic in vivo studies in the last decade.
6

In the late 1980’s, a commentary by Steven McKnight and Dan Lane indicated that
C/EBPα was a metabolic regulator of energy metabolism (52). Since that time numerous studies
have confirmed the role of C/EBPα and other C/EBP family members in energy balance and
defined roles for these transcription factors in adipocyte differentiation (reviewed in (53)). In
1994, two prominent laboratories independently identified PPARγ as an important modulator of
adipocyte differentiation. Studies by Dr. Mitch Lazar’s group observed the induction of PPARγ
during adipogenesis (54), and experiments by Dr. Bruce Speigelman’s laboratory revealed that
PPARγ was a transcription factor which bound to an enhancer element in the aP2 promoter and
conferred its fat specific expression (55). The early 1990s was also the time that Brown and
Goldstein identified SREBP-1 (56), also termed ADD1, whose expression was also observed to
play a role in adipocyte determination by the Speigelman laboratory (57). Since this time,
several other transcription factors have been found to play an important role in adipocyte
differentiation. This section will focus on the transcription factors mentioned above and other
important transcription factors that are regulated during adipocyte differentiation and are known
to contribute to this process.
Studies of the aP2 gene or use of its regulatory sequences have led to significant
discoveries in adipocyte biology. aP2 is an abundantly expressed adipocyte gene that was first
discovered in 1984 (58). One of the earliest studies on PPARγ identified it as a transcription
factor that bound to an enhancer element in the aP2 promoter and conferred its fat-specific
expression. Since its discovery, the aP2 promoter has been used by hundreds of laboratories to
construct transgenes that have largely fat-specific expression. A lesser known historical fact is
that c-fos was also shown to bind to the aP2 promoter just 124 base pairs upstream of the
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transcriptional start site (59). As means of introduction, this was the first study to propose that
AP-1 proteins were regulators of adipocyte gene expression.
Activating Protein (AP-1) Transcription Factors: Members of the activating protein-1 (AP-1)
family of transcription factors are well-known regulators of cellular proliferation and
differentiation. AP-1 is a collective term referring to dimeric transcription factors composed of cJun, JunB, JunD and c-Fos, FosB, Fra-1, or Fra-2 subunits that bind to a common DNA site, the
AP-1-binding site (reviewed in (60). As indicated above, studies by the Spiegelman laboratory
indicated that c-fos was involved in the modulation of aP2 expression (59). Several years later, it
was shown that the expression of c-jun, c-fos, jun-B, fos-B, and fra-1 was induced immediately
after the induction of adipocyte differentiation (61;62). Although the role of individual AP-1
family members in adipogenesis has not been elucidated, there is strong evidence to indicate the
importance of these transcription factors in vivo. Transgenic mice were generated that express a
dominant-negative protein that prevents the DNA binding of B-ZIP transcription factors of both
the C/EBP and Jun families under the control of the adipose-specific aP2 enhancer/promoter.
These mice have no white adipose tissue throughout life (14). Collectively, these studies suggest
that the induction and expression of AP-1 transcription factors are important in fat cell
differentiation.
Krüppel-like Factors (KLFs): Krüppel-like zinc finger transcription factors (KLFs) are known
to play diverse roles in cell differentiation and development in mammals. One protein in the KLF
family, KLF15, was shown to be highly induced during the differentiation of 3T3-L1
preadipocytes into adipocytes (63). Inhibition of KLF15 function or expression with a dominant
negative mutant or via RNA interference results in an inhibition of adipogenesis in 3T3-L1 cells
(63). These studies also revealed that KLF15 could confer adipogenesis in non-precursor cells
8

and result in the induction of PPARγ expression. Similar to KLF15, KLF5 expression is also
highly induced during adipocyte differentiation in 3T3-L1 cells, and embryonic fibroblasts
obtained from heterozygote KLF5(+/-) mice exhibit reduced adipogenesis (64). Another member
of this family, KLF2, has been shown to be a negative regulator of adipogenesis and has the
ability to attenuate PPARγ expression (65). KLFs are not only involved in lipid accumulation,
but also appear to play a role in the ability of the adipocyte to be insulin sensitive, as indicated by
studies showing that KLF15 is important in the expression of GLUT4 (66). KLF4 is also
induced early in the differentiation process and can transactivate the C/EBPβ promoter in
cooperation with Krox20 (67), another zinc finger transcription factor shown to stimulate
adipogenesis (68). Other members of the KLF family have been shown to have differential
effects on adipogenesis; hence, emerging studies on the role of KLFs in adipocyte development
will be critical for the identification of target genes in fat cells, as well as the likely discovery of
both redundant and non-redundant functions of these transcription factors in adipocytes.
Sterol Regulatory Element Binding Proteins (SREBPs): In 1993, studies by the Spiegelman
group identified a basic helix-loop-helix transcription factor that was expressed in adipocytes and
whose expression was increased during adipogenesis (57). The protein was called ADD1 for
adipocyte differentiation and determination. Two months later, this protein was labeled SREBP1 by the Brown and Goldstein’s laboratories, who named the transcription factor for its ability to
bind sterol responsive elements within the promoter of the low-density lipoprotein (LDL)
receptor gene (56). It is now known that there are three SREBP isoforms (SREBP-1a, -1c, and 2) that have been well characterized in the last fifteen years. SREBP-1a and -1c are transcribed
from the same gene, each by a distinct promoter, and the predominant SREBP-1 isoform in liver
and adipose tissue is SREBP-1c. SREBP-2 is relatively selective in transcriptionally activating
9

cholesterol biosynthetic genes, and SREBP-1c has a greater role in regulating genes associated
with fatty acid synthesis (reviewed in (69). Although there is clear evidence that SREBP is an
insulin modulated transcription factor that is involved in the regulation of genes associated with
cholesterol and lipid metabolism, studies indicate that SREBPs may not be critical for
adipogenesis. Mice deficient in SREBP-1 do not have a significantly decreased amount of white
adipose tissue, but SREBP-2 levels were increased suggesting it might compensate for SREBP-1
(70). These in vivo studies are supported by additional transgenic studies where the SREBP-1
deficient mice were crossed with ob/ob (leptin deficient) mice, and it was found that SREBP-1
was not required for the development of obesity. These observations demonstrated that SREBP-1
regulation of lipogenesis was highly involved in the development of fatty livers but was not a
determinant of obesity in this animal model (71). However, ectopic expression of a dominantnegative SREBP-1c was shown to attenuate adipocyte differentiation (72). In addition, over
expression of SREBP-1c enhanced the adipogenic activity of PPARγ (72) and other studies
suggest that SREBP-1c contributes to the generation of PPARγ ligands (73). In summary, in
vitro studies support a role for SREBP-1 in adipogenesis, whereas in vivo studies indicate that
SREBPs are not required for the production or expansion of adipose tissue.
CAAAT Enhancer Binding Proteins (C/EBPs): C/EBP transcription factors were the first
family of proteins shown to play a critical role in the differentiation of fat cells in vitro. Today,
we know that transgenic mice lacking both C/EBPβ and C/EBPδ or C/EBPα alone have defective
adipocyte differentiation (74;75). Prior to these in vivo observations, the cascade of induction of
these three C/EBP family members was revealed by McKnight and collaborators who showed
that C/EBPs β and δ were induced immediately after the induction of differentiation, whereas
C/EBPα expression did not occur until four to five days after the initiation of differentiation (76).
10

This group also demonstrated that C/EBPs β and δ were responsible for inducing C/EBPα
expression (77). Ectopic expression studies conducted by several laboratories demonstrated the
adipogenic capabilities of C/EBPα or C/EBPβ alone, or in the presence of C/EBPδ (77-80).
Today, C/EBPα and PPARγ are considered the two primary transcription factors that mediate
adipogenesis. However, cells lacking C/EBPα are capable of adipogenesis, but are not insulin
sensitive (81;82). There is also evidence to indicate that C/EBPs may play a role in the induction
of a PPARγ ligand (83). In summary, both in vitro and in vivo studies indicate a substantial role
for C/EBPβ, C/EBPδ and C/EBPα in adipogenesis. Although C/EBPα may not be required for
lipid accumulation, this transcription factor clearly plays a role in conferring insulin sensitivity in
adipocytes.
Peroxisome Proliferator-Activated Receptors (PPARs): Although a number of transcription
factors, including those mentioned above, have been shown to have profound effects on fat cell
differentiation and the expression of adipocyte genes, only one adipocyte transcription factor has
been shown to be necessary for adipogenesis. Peroxisome proliferator-activated receptor gamma
(PPARγ) is a member of the nuclear hormone receptor superfamily that is required for the
development of adipocytes, and deletion of PPARγ in mice results in placental dysfunction and
embryonic lethality (84;85).

As mentioned above, PPARγ was originally identified as a

transcription factor induced during differentiation that bound to the enhancer element within the
aP2 promoter (86). Since that time, there have been multiple studies on the role of PPARγ in
adipocytes. A remarkable finding in 1995 was that the insulin sensitizing drugs
thiazolidinediones were ligands for PPARγ (87). These were some of the first molecular studies
to indicate the importance of adipose tissue in insulin resistance. Many investigators were
surprised to learn that activating a transcription factor whose expression was highly enriched in
11

fat cells could contribute to whole animal insulin sensitivity. It is now known that adipocytes
secrete several hormones that can affect the activity of other tissues; however, the studies of
PPARγ have revealed that modulation of this transcription factor can contribute to systemic
insulin resistance. Although the PPARγ null mice are embryonic lethal (85), transgenic mice
lacking PPARγ specifically in adipose tissue exhibit greatly reduced sized fat pads and insulin
resistance in fat and liver (88). However, PPARγ heterozygote mice(+/-) have enhanced insulin
sensitivity (89). Together, these studies suggest the amount of PPARγ in adipose tissue is
physiologically relevant. In the last several years, several studies have examined pathways that
are involved in regulating the levels of PPARγ. In particular, the ubiquitin-proteasome system
has emerged as an important regulator of PPARγ proteins (90;91). In addition, a role for the
ubiquitin-like protein, SUMO (Small Ubiquitin-like Modifier) in regulating PPARγ has been
demonstrated by several groups (92-95). The phosphorylation of PPARγ by MAPKs is also an
important modulator of the activity of this transcription factor (reviewed in (96). A very recent
study confirmed that PPARγ knockdown prevented adipocytes differentiation, but was not
required for maintenance of the adipocyte differentiation state after the cells had undergone
adipogenesis (97). These findings are supported by many anecdotal observations that indicate
that PPARγ is decreased as adipocytes age in vitro. In addition, the increase of life span via
caloric restriction results in the induction of Sirt1, a transcriptional modulator with deacetylase
activity, that represses PPARγ activity in vivo (98). This study also demonstrated that the
repression of PPARγ by Sirt1 was evident in 3T3-L1 adipocytes. Collectively, studies by
numerous laboratories demonstrate the adipogenic capabilities of PPARγ. However, the role of
this transcription factor in mature adipocytes is not well understood, and recent studies suggest
that this transcription factor is not required for maintenance of the adipocyte following
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adipogenesis (97). Nonetheless, PPARγ expression and activity is controlled at multiple levels,
including alternative promoter usage, tissue limited expression, phosphorylation, acetylation,
ubiquitylation, and SUMOylation. The multiple regulatory features of this transcription factor
suggest that controlling the amount and activity of PPARγ is important. The role of PPARγ in
the development and treatment of diabetes is well established (reviewed in (99)), and the
importance of PPARγ in humans is indicated by several loss-of-function mutations in the PPARγ
gene that cause lipodystrophy and diabetes (100-102) (reviewed in (103)).
Signal Transducers and Activators of Transcription (STATs): The janus kinase/signal
transducer and activator of transcription (JAK/STAT) pathway was identified by studying the
transcriptional activation of genes in response to cytokine/growth factors (reviewed in (104-106).
Cytokines induce a broad range of effects on a number of biological processes and activate
receptors that do not contain any obvious cytoplasmic catalytic domains. To date, there are four
members in the JAK kinase family (JAKs 1-3 and Tyk 2) that have been identified and shown to
associate with cytokine/growth factor receptors and result in the activation of a signal
transduction cascade involving STAT proteins.
The STAT family of mammalian transcription factors is comprised of seven proteins
(STATs 1, 2, 3, 4, 5A, 5B, 6) which, in response to stimulation of various receptors, are
phosphorylated on tyrosine residues causing their translocation to the nucleus. Each STAT
family member shows a distinct pattern of activation by different ligands, and upon nuclear
translocation can regulate the transcription of particular genes. The order of events for STAT
activation can be briefly described as follows: 1) Ligand binds cell surface receptor; 2) receptor
associates with a JAK family member; 3) JAK tyrosine phosphorylates receptor 4) STAT
associates with phosphorylated receptor and is phosphorylated by JAK 5) STATs form dimers
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and translocate to the nucleus; and 6) STATs bind DNA and modulate transcription. STATs
have been shown to bind distinct DNA sequences, and this binding regulates the transcription of
specific genes (reviewed in (105;107)). Since the tissue distribution and function of each STAT
is unique, the regulation of tissue-specific genes may be a physiological role for these proteins
(reviewed in (108)). This hypothesis is supported by numerous reports which demonstrate that
specific STATs are activated differently by growth factors and cytokines, and STAT activation
can be cell type dependent. In addition, transgenic knockout experiments have revealed crucial
roles for each known mammalian STAT (reviewed in (105)), and cell-specific functions for
STAT family members have been identified (reviewed in (106)). STATs have been shown to
play a role in many processes, including oncogenesis, vascular disease, myeloproliferative
disorders, diabetic nephropathy, and energy balance.
Two STAT family members, STAT5A and STAT5B, are highly related, but are encoded
for by two separate genes (109). Murine STAT5A and 5B have 96% sequence similarity, and
the major difference between the two proteins is at the C-terminus, where the final eight residues
are different. Also, STAT5B is 12 residues shorter than STAT5A. Interestingly, STATs 5A and
5B have been shown to have both essential and nonessential, or redundant, roles in cytokine
responses (110). Several studies indicated that STAT5 proteins can be activated by a number of
different cytokines, yet STAT5 null mice have a phenotype that is consistent with these two
STAT5 proteins being primarily activated by growth hormone (GH) and prolactin (PRL) (110).
In addition to its role in growth, GH plays a role in energy metabolism. Over ninety
years ago, it was shown that the anterior pituitary was the source of a factor that exerted
profound effects on glucose metabolism. It is now known that GH plays a critical role in
modulating a variety of metabolic pathways, including lipolysis, lipogenesis, glucose uptake, and
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protein synthesis (reviewed in (111)).

Overall, GH promotes growth of lean tissue while

reducing accumulation of fat in adipose tissue. Mice with GH excess are lean and resistant to
diet induced obesity, but are severely insulin resistant (112;113). In contrast, mice with chronic
GH deficiency (114;115) have increased insulin sensitivity despite increased adiposity
(112;114;115). Increased adipose tissue mass occurs in GH-deficient children and adults (116118), and treatment of GH-deficient patients with exogenous GH can improve lean body mass
while reducing fat mass (119-121). These advantageous effects of GH have generated interest in
using GH or analogs in the treatment of several types of obesity (122-124), despite the likelihood
that GH treatment may exacerbate glucose intolerance and hyperinsulinemia (reviewed in
(125;126)). Several studies have shown that activation of STATs 5A and 5B are critical for a
variety of GH functions, including changes in metabolism, body growth, and sex-dependent gene
regulation (110)(reviewed in (125;126)).
PRL is a peptide hormone primarily known for its role in mammary gland development
during lactation, but it has been shown to have pleiotrophic effects in a variety of tissues
(reviewed in (127)). PRL activates multiple signal transduction pathways, including MAPK
(reviewed in (128)) and PI3K reviewed in (129)); however, the JAK/STAT pathway is the
predominant signaling cascade activated by PRL, resulting in the nuclear translocation of
STAT5 proteins (reviewed in (130)).

The regulation of mammary tissue by PRL is well

described, but there is also evidence that PRL modulates adipose tissue. The prolactin receptor
(PRL-R) is expressed in both mouse (131) and human adipose tissue (reviewed in (132)) and is
induced during adipogenesis (133). Ectopic expression of the PRL-R in NIH-3T3 cells confers
adipocyte conversion and activation of the aP2 promoter in a PRL-dependent manner (134).
Collectively, these observations strongly suggest a role for PRL in the regulation of adipocte
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function. Furthermore, the occurrence of obesity has been correlated with hyperprolactinomas in
humans (135). In addition to these adipogenic effects, PRL has been shown to induce lipolysis
in rabbits (136) and mouse adipose tissue explants (137) . Studies have shown that PRL reduces
lipoprotein lipase (LPL) activity in cultured human adipocytes (reviewed in (132)) and decreases
the activity of LPL and fatty acid synthase (FAS) in adipose tissue of lactating mice (138).
Thus, PRL exerts adipogenic and anti-lipogenic effects on adipose tissue in a variety of species,
and several of which may be mediated by STAT proteins.
In the last decade, several groups have studied the modulation and function of STAT
proteins during adipogenesis and in mature fat cells. The first studies on STAT expression in
3T3-L1 cells revealed that STATs 1, 5A and 5B were highly induced during murine
adipogenesis (139). Similar results were observed during the in vitro differentiation of human
preadipocytes (140). In addition, the ectopic expression of C/EBPs β and δ in non-precursor cells
results in an induction of adipogenesis (79) that is accompanied by an induction in STAT5A and
STAT5B protein levels (141). These two STAT proteins were also coordinately regulated with
both PPARγ and C/EBPα in differentiating 3T3-L1 cells under a variety of different conditions
(142). In 3T3-F44A preadipocytes, the ability of GH to modulate adipogenesis was attenuated by
STAT5 anti-sense oligonucleotides (143). Also, constitutively active STAT5 was capable of
replacing the requirement for GH in adipogenesis of these cells (144). Moreover, ectopic
expression of STAT5A has been shown to confer adipogenesis in 3T3-L1 preadipocytes (145)
and in two different non-precursor cell lines (146). Interestingly, STAT5B was not capable of
conferring adipogenesis in non-precursor cells (146). Transgenic deletion of STAT5A, STAT5B,
or both STAT5 genes in mice resulted in significantly reduced fat pad sizes compared to wildtype mice (110). Also, in primary cultures of adipose tissue from these animals, GH did not
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stimulate lipolysis as it did in adipocytes from wild-type animals (147) suggesting that some of
the effects of GH on fat metabolism are dependent on STAT5 proteins. It should be noted that
the increased expression of STAT5 proteins is not typically observed until after the induction of
C/EBPα and PPARγ (refer to Figure 1.1), yet the activation of STAT5 proteins in preadipocytes
occurs prior to the induction in expression of PPARγ in 3T3-L1 cells (146). In fact, both STAT5
proteins are tyrosine phosphorylated and translocate to the nucleus within 15 minutes after the
induction of adipogenesis of preadipocytes (146;148). Coupled with the observations in STAT5
null mice, which have fat pads of one-fifth normal size (110), the data suggest that activation of
STAT5 proteins may be an important driver of adipogenesis both in vitro and in vivo. This
hypothesis is also supported by work indicating that one of the PPARγ promoters can be
modulated by STAT5 (149), suggesting that STAT5 activation might drive adipogenesis by
inducing PPARγ expression. In summary, work by a variety of laboratories in the last decade has
demonstrated that STAT5 proteins, particularly STAT5A, are activated and induced during
adipogenesis and play an important role in adipose tissue development.
In addition to the transcription factors described above that promote adipogenesis, there
are several other transcription factor families that have been shown to have positive or negative
effects on adipocyte differentiation (reviewed in (53;150)). The expression and activity of these
transcription factors play a profound role in modulating a vast array of target genes that are
important in conferring lipid accumulation, insulin sensitivity, and endocrine properties in
mature fat cells. The identification and characterization of the target genes of adipogenic
transcription factors has provided critical information in understanding the role of these proteins
in both adipocyte differentiation and in adipose tissue. Adipogenesis occurs as a result of a
transcriptional cascade that involves the tightly regulated induction of numerous transcription
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factors, including STAT5, SREBP-1c, PPARγ and several members of the C/EBPs and KLF
families (refer to Figure 1.1). In addition, many of these adipogenic factors possess the ability to
regulate one another’s gene expression, and there is substantial evidence to support functional
redundancy in the ability of some of these transcription factor families to confer adipocyte
development in vitro and in vivo. The future study of transcription factors that modulate
adipocyte development and function is important and will likely continue to provide insight into
our understanding of metabolic diseases including obesity and type II diabetes.

Figure 1.1 Transcription factor activation or expression during adipogenesis
1.3 Identification of STAT5 Target Genes
As previously stated, adipogenesis occurs as a result of a transcriptional cascade that
involves a tightly regulated induction of key transcription factors- one of which is STAT5. It is
critical to identify the target genes of these adipogenic transcription factors in order to
understand adipocyte gene expression and fat cell function. STAT5 proteins play a vital role in
the regulation of genes involved in lipid metabolism and insulin resistance in adipocytes, and this
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section will focus on specific target genes that have been identified. The identification and
characterization of these target genes has provided critical information in understanding the role
of STAT proteins in both differentiating and mature fat cells.
It is widely accepted that STAT proteins have cell-specific functions. Studies on STAT5
proteins have revealed their importance in adipogenesis in vitro and in vivo (110;146). In
addition to their role in promoting adipocyte differentiation, STAT5 proteins also exert effects on
mature adipocytes. Recent studies have focused on the identification of STAT5 target genes in
adipocytes. The promoter for acyl CoA oxidase (AOX), the rate limiting enzyme in peroxisomal
fatty acid β-oxidation, contains a STAT5 binding site that modulates its gene expression in fat
cells (151). Another study indicates that GH also exerts stimulatory effects on adipogenesis
through STAT5A and 5B by enhancing the transcriptional activity of C/EBPβ/δ and PPARγ
(149). Transfection studies demonstrated that aP2 promoter activity can be activated by STAT5
(134). Yet, other studies have shown that STAT5 mediates the inhibition of aP2 expression in rat
primary preadipocytes (152). These were the first studies to suggest that STAT5 proteins could
act as a transcriptional repressor. Another study has also revealed that STAT5 can act as a
transcriptional repressor in adipocytes: a STAT5A binding site in the murine FAS promoter has
been shown to mediate the repression of FAS transcription that occurs with PRL treatment (153).
It is well known that PRL and GH are important modulators of lipid metabolism and are
also potent inducers of STAT5 in adipocytes (134;154). Hence, many of the metabolic actions of
these hormones could be mediated by STAT5’s direct modulation of target genes.
Unfortunately, relatively few STAT5 target genes have been identified in adipocytes.
Nonetheless, we hypothesize that several other STAT5A target genes will be identified that play
a role in lipid or glucose metabolism.
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1.4 gp130 Cytokines
In addition to STATs 5A and 5B, other STAT proteins have been shown to be expressed
in adipocytes (139). Therefore, our studies also focus on plausible roles for these STATs, as
well as their activators. The Interleukin (IL)-6 family of cytokines is a group of functionally and
structurally related proteins that include Interleukin-6 (IL-6), Interleukin-11 (IL-11), Interleukin27 (IL-27), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor
(CNTF), cardiotrophin-1 (CT-1), novel neurotrophin-1/B cell stimulating factor-3 or
cardiotrophin-like cytokine (CLC), and neuropoietin (NP) (155;156)(reviewed in (157)). All
members of this family utilize glycoprotein 130 as a common transducer protein in their
functional receptor complex that is required for signaling; therefore, the IL-6 family of cytokines
is commonly referred to as the gp130 cytokines. These cytokines are involved in the regulation
of numerous biological processes, including hematopoiesis, immune response, inflammation,
differentiation, mammalian reproduction, cardiovascular action, and neuronal survival (reviewed
in (157)).

Gp130 cytokine signal transduction involves the activation of the JAK/STAT

pathway, typically activating STAT3 and, to a lesser extent, STAT1.

Though originally

characterized as having unique properties, gp130 cytokines are known to function in a
pleiotropic and redundant manner. The shared usage of signal transducers in the receptor
complexes may explain the functional redundancy of gp130 cytokines. Gp130 is ubiquitously
expressed in every cell type, which allows for the pleiotropic nature of the cytokines on a variety
of cells. Also, though all of these cytokines share gp130 in their receptor complex, they are
differentially regulated in multiple tissues, due to the presence of other receptor components that
are required for their activation, including the LIF receptor and the cytokine’s specific α receptor
(refer to Figure 1.2). Interleukin-6 (IL-6) and interleukin-11 (IL-11) first bind to IL-6 receptor α
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and IL-11 receptor α (158), respectively, and then recruit a gp130 homodimer complex for
signaling.

Interleukin-27 (IL-27) engages a gp130/WSX-1 heterodimeric receptor complex

(155). Leukemia inhibitory factor (LIF) and oncostatin M (OSM) directly bind the gp130/LIF
receptor (LIFR) complex to induce signal transduction; OSM can alternatively utilize a
gp130/OSM receptor (OSMR) complex. Cardiotrophin-1 (CT-1) recruits an alpha receptor
(159), which to date has not been characterized, and also signals via gp130/LIFR. Ciliary
neurotrophic facor (CNTF), cardiotrophin-like-cytokine (CLC), and neuropoietin (NP) all recruit
CNTFRα and then induce the formation of a gp130/LIFR heterodimer for signal transduction
(156;160;161).
In recent years, gp130 cytokines have become a focus of attention in the scientific
community, as they have been implicated as potential therapeutic targets in obesity (162).
Studies have shown that adipocytes are responsive to gp130 cytokines (154;163-167); however,
their functions, as well as their complex signaling cascades, in adipose tissue have been only
partially elucidated. Findings in our laboratory indicate that several gp130 cytokines have
differential effects on adipogenesis (166-168), as well as insulin-stimulated glucose uptake (165168). In addition, gp130 cytokines have the unique ability to crosstalk with other members of
the gp130 family to alter one another’s signaling (169). An in-depth analysis of the mechanisms
underlying gp130 signaling and crosstalk will enable us to further understand their role in
adipocytes.
Research Focus: Overall, the goal of fat cell research is to analyze adipocytes both in cell
culture and in animal models to determine how modifications in their function can contribute to
metabolic diseases, namely obesity and T2D. Specifically, our lab observes the modulation of
important transcription factors that regulate fat cell development and are involved in both the
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Figure 1.2 Several gp130 cytokines and their receptors.
induction and/or maintenance of adipocyte gene expression.

The work included in this

dissertation will highlight the differential actions of various activators of the STAT family of
transcription factors in adipocytes. STAT proteins have been shown to have significant roles in
adipocyte development and function. In addition to modulating genes associated with lipid
metabolism, our novel studies indicate that STAT5 can also modulate a gene associated with
glucose metabolism. Pyruvate dehydrogenase kinase (PDK)-4, a known regulator of glycolysis,
is highly induced in adipocytes by GH or PRL in a STAT5 dependent manner (170), and this
induction is associated with insulin resistance.
Target genes modulated by other STAT proteins, such as STAT3, have not been fully
characterized. However, our laboratory has demonstrated that gp130 cytokines, which are potent
STAT3 activators, exert numerous differential effects on adipocytes. The gp130 family has been
shown to affect important adipocyte properties, including insulin sensitivity and fat cell
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development. Our novel data reveal that NP has inhibitory effects on adipogenesis, insulin
signaling, and insulin-stimulated glucose uptake. Importantly, although several gp130 cytokines
possess the ability to alter the subsequent signaling of other family members both in vitro and in
vivo, NP does not crosstalk in the same manner. We also demonstrate that NP does not activate
or induce the degradation of the LIFR, though previously reported to do so, and this may be the
reason for NP’s unique action.
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CHAPTER 2
THE STAT5A-MEDIATED INDUCTION OF PYRUVATE
DEHYDROGENASE KINASE 4 EXPRESSION BY PROLACTIN OR
GROWTH HORMONE IN ADIPOCYTES1
2.1 Introduction
It is well known that growth hormone (GH) and prolactin (PRL) induce signaling via the
JAK-STAT pathway. In particular, STAT5 proteins are potently activated by these hormones
(reviewed in (171)). GH is known to have profound effects on lipid metabolism (reviewed in
(172)). The effects of PRL have been well characterized in mammary tissues, yet there is also
evidence demonstrating that this hormone can affect adipose tissue in mice and humans
(131)(reviewed in (132). Yet, few molecular targets for the STAT5-mediated actions of GH and
PRL on adipocytes have been identified. Although, multiple lines of recent evidence suggest that
STAT5 proteins can modulate adipocyte function (110;141;143-147), very few studies have
identified direct STAT5 target genes in adipocytes. We recently observed that the GH and PRL
inhibition of fatty acid synthase (FAS) transcription was mediated by a STAT5A binding site in
the rat FAS promoter (153). Hence, our current efforts have been to identify other genes
associated with glucose or lipid metabolism that are directly modulated by STAT5 proteins in
adipocytes. In this study, we present data demonstrating that pyruvate dehydrogenase kinase
(PDK)4 is a STAT5A target gene.
PDK is family of kinases that negatively regulate the activity of the pyruvate
dehydrogenase complex (PDC) (reviewed in (173)). There are four tissue specific isoforms of
PDK, PDK1-4, that have been identified in mammals (174), and each has different patterns of

1
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gene expression (174-176). The specificity in distribution, expression, and activity of each PDK
isoform contributes to the long-term regulation of PDC in a given tissue, and thus, in part,
regulates glucose metabolism. There are several conditions that result in the short term regulation
of PDC activity (177)(reviewed in (178;179)). The long term regulation of PDK that occurs in
starvation (reviewed in (179))(180) and diabetes involves an increase in the amount of PDK
protein, which results in stable increases in PDK activity (181).
An induction of PDK4 leads to decreased glucose oxidation, which results in
hyperglycemia. PDK4 expression has also been shown to be induced by high-fat feeding in
skeletal muscle (182). A study in nondiabetic Pima Indians, a group prevalently stricken with
obesity and type 2 diabetes, has demonstrated that increased levels of muscle PDK4 expression
positively correlate with increased fasting plasma levels of insulin and negatively correlate with
insulin-mediated glucose uptake (183). It has also been documented that insulin has the ability to
suppress PDK4 expression in skeletal muscle and hepatoma cells (183-185). Increased insulin
sensitivity in postobese patients has also been shown to be associated with decreased PDK4
expression (186).
In our present study, we examined the modulation of PDK4 in adipose tissue. Our
studies clearly demonstrate that PRL and GH can induce the expression of PDK4 in 3T3-L1
adipocytes. Our studies also show that insulin pretreatment has the ability to attenuate the ability
of these hormones to induce PDK4 expression. In addition, we identified a hormone sensitive
region in the murine PDK4 promoter and characterized a STAT5 binding site in this region,
which mediates the hormonal affects on PDK4 expression. Also, when PDK4 protein was
induced, we observed an inhibition in insulin stimulated glucose uptake. In summary, our studies
indicate that PDK4 can be induced in adipocytes and may play a role in insulin resistance.
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2.2 Materials and Methods
Materials. Dulbecco’s modified Eagle medium (DMEM) was purchased from Invitrogen. Fetal
bovine serum (FBS) was purchased from Atlanta Biologicals, and calf serum was purchased
from Biosource. PDK4 antibodies were purchased from Abgent. Porcine and human growth
hormone and sheep prolactin were purchased from Sigma. STAT5A antibodies were purchased
from Santa Cruz. Active MAPK was purchased from Promega. [α-32P] dCTP was purchased
from Perkin-Elmer and Amersham Biosciences. Deoxynucleotide thymine triphosphate, dATP,
and dGTP were purchased from Amersham Biosciences. Oligonucleotides were purchased from
Integrated DNA Technologies. DNAse polymerase I large (Klenow) fragment was purchased
from Promega.
Cell Culture. Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in
DMEM containing 10% bovine serum. Medium was changed every 48 h. Cells were induced to
differentiate by changing the medium to DMEM containing 10% FBS, 0.5 mM 3-isobutylmethylxanthine, 1 μM dexamethasone, and 1.7 μM insulin (MDI). After 48 h, this medium was
replaced with DMEM supplemented with 10% FBS, and the cells were maintained in this
medium until utilized for experimentation. For serum deprivation, cells that were between 7-10
days post MDI were placed in DMEM supplemented with 0.15% fatty-acid free and growth
factor depleted BSA for 16-20 hours.
Preparation of Whole Cell Extracts. Cell monolayers were rinsed with PBS and then harvested
in a non-denaturing buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 μM phenylmethylsulfonyl fluoride, 1 μM
pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium
vanadate. Samples were extracted for 30 min on ice and centrifuged at 15,000 rpm at 4oC for 15
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min. Supernatants containing whole cell extracts were analyzed for protein content by BCA
analysis (Pierce) according to the manufacturer’s instructions.
RNA Analysis. Total RNA was isolated from cell monolayers with Trizol (Invitrogen) according
to manufacturer’s instructions with minor modifications. For Northern blot analysis, 15 μg of
total RNA was denatured in formamide and electrophoresed through a formaldehyde/agarose gel.
The RNA was transferred to Zeta Probe-GT (Bio-Rad) in a buffer containing 75 mM sodium
citrate tribasic, 10 mM NaOH and 750 mM NaCl. Probes were labeled by random priming using
Klenow fragment and [α-32P] dCTP.
Plasmid Constructs: A 973 nucleotide segment of the PDK4 promoter (-949 to +24) was cloned
from murine Sv/129 liver genomic DNA using the following PCR primers: forward
ATGACCCGCTAGCATGTTTC; reverse GGTGAAGGGTTGACACTTGG. Nucleotides were
added to the 5’ ends of each primer so that the forward primer could be digested by KpnI and the
reverse primer by SacI for directional ligation into the multiple cloning site of pGL3-basic
KpnI/SacI to create pGL3-PDK4pro. The STAT element in pGL3-PDK4pro (TTCTTGGAA)
was mutated to (TTTATGGAA) using the QuickChange II Site Directed Mutagenesis Kit
(Stratagene)

with

the

following

primer

and

CACGCTCCGCGGTGAGATTTATGGAAACAGTTTCTGGCTAG,

its
to

create

antisense,
pGL3-

PDK4mut. Plasmids were sequenced for verification of wild type and mutagenic nucleotide
sequences using Big Dye Terminator Extension Reactions (ABI).
Transfections and Luciferase Reporter Assays: 3T3-L1 adipocytes in 6-well plates were
transfected on day 3 of differentiation following addition of DMEM containing 10% fetal bovine
serum and 425 nM insulin. Either 2.5 µg of pGL3-PDK4pro or 2.5 µg of pGL3-PDK4mut was
cotransfected with 250 ng of pRL-CMV/renilla vector to control for transfection efficiency in
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each well using Fugene 6 (Roche). After 32h, cells were serum-deprived overnight in DMEM
with 0.15% BSA, then untreated or treated with prolactin for 2h or 4h and harvested. Cell lysates
were assayed for firefly and renilla luciferase using the Dual Luciferase Reporter System
(Promega). Relative light units (RLU) were calculated by dividing firefly luciferase activity
values by renilla luciferase.
Preparation of Nuclear and Cytosolic Extracts. Cell monolayers were rinsed with PBS and
then harvested in a nuclear homogenization buffer (NHB) and centrifuged to isolate cytosolic
and nuclear extracts as previously described (169).
Gel Electrophoresis and Immunoblotting. Proteins were separated in 6% polyacrylamide
(National Diagnostics) gels containing sodium dodecyl sulfate (SDS) according to Laemmli
(187) and transferred to nitrocellulose (Bio-Rad) in 25 mM Tris, 192 mM glycine, and 20%
methanol. Following transfer, the membrane was blocked in 4% milk overnight at 4oC. Results
were visualized with horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories) and enhanced chemiluminescence (Pierce).
Electrophoretic Mobility Shift Analysis. Double-stranded oligonucleotides were filled-in with
[α-32P] dCTP using Klenow. Binding reactions were performed with nuclear extracts, according
to Ritzenthaler et al (188). The sequence of the oligonucleotide used was 5’GTGAGATTCTTGGAAACAGTT-3’. Protein-DNA complexes were resolved and visualized,
as previously described (153). For supershift analysis, nuclear extracts were preincubated with 4
μg of antibody for 1 h at room temperature.
Determination of [3H] 2-Deoxyglucose Uptake - The assay of [3H] 2-deoxyglucose uptake was
performed as previously described (189). Prior to the assay, fully differentiated 3T3-L1
adipocytes were serum deprived for 4 hours. Uptake measurements were performed in triplicate
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under conditions where hexose uptake was linear. The results were corrected for nonspecific
uptake, and absorption was determined by [3H] 2-deoxyglucose uptake in the presence of 5 μM
cytochalasin B. Nonspecific uptake and absorption was always less than 10% of the total uptake.
2.3 Results
Several previous studies have demonstrated an induction of PDK4 in skeletal muscle
(182;184); but, the induction of PDK4 expression in adipocytes has not been previously
examined. In the course of studying activators of STAT5A, we observed an induction of PDK4
mRNA by PRL. Total RNA was isolated from fully differentiated 3T3-L1 adipocytes after
treatment with PRL for the times indicated. PRL is known to induce the expression of SOCS
(suppressors of cytokine signaling)-3.

As shown in Figure 2.1, the efficacy of PRL was

demonstrated via the induction of SOCS-3, which occurred following a 30 min treatment. In
addition, PRL induced the expression of PDK4 mRNA as evidenced by the robust expression at
2 hours. Between 2 and 6 hours, the induced PDK4 mRNA was apparent. In addition, PRL did
not have any substantial effect on the expression of PDK2. Ethidium bromide staining of 28S
and 18S RNA was included as a loading control.
To further examine the modulation of PDK4 by PRL, fully differentiated 3T3-L1
adipocytes were treated with various doses of PRL for 2 hours. As shown in Figure 2.2, PRL
treatment resulted in a dose dependent increase in PDK4 mRNA. Physiological levels of
prolactin, 0.5 nM (12 ng/ml), were capable of inducting PDK4 mRNA. An analysis of β-actin
mRNA levels is included as a loading control.
Because PRL is a potent STAT 5 activator, we also examined the effect of growth
hormone (GH), another hormone known to activate STAT 5 in adipocytes. As shown in Figure
2.3, a 2-h treatment with sheep PRL or porcine GH resulted in an induction of PDK4 mRNA.
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Figure 2.1 Prolactin induces PDK4 expression in a time dependent manner in 3T3-L1
adipocytes. Total RNA was isolated from serum deprived 3T3-L1 adipocytes following 20 nM
(480 ng/ml) prolactin treatment for the times indicated. Untreated cells (0) were also harvested at
the start of the time course. Fifteen μg of total RNA was electrophoresed, transferred to nylon,
and subjected to Northern blot analysis with radiolabeled probes for PDK4, PDK2, and SOCS-3.
Ethidium bromide staining of 28S and 18S RNA is also included. This is a representative
experiment independently performed four times.

Figure 2.2. Prolactin induces PDK4 expression in a dose dependent manner in 3T3-L1
adipocytes. Total RNA was isolated from serum deprived 3T3-L1 adipocytes following
prolactin treatment with the doses indicated. Untreated cells (0) were also harvested at the start
of the experiment. Fifteen μg of total RNA was subjected to Northern blot analysis. This is a
representative experiment independently performed three times.
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Figure 2.3 Both Prolactin and porcine Growth Hormone induce PDK4 expression in 3T3-L1
adipocytes. Total RNA was isolated from serum deprived 3T3-L1 adipocytes following a 2 hour
treatment with 0.5 nM prolactin (P), human growth hormone (h), or porcine growth hormone (p).
Untreated cells (CTL) were also harvested at the start of the experiment. Fifteen μg of total RNA
was electrophoresed, transferred to nylon, and subjected to Northern blot analysis with
radiolabeled probes for PDK4 and β-actin. Ethidium bromide staining of 28S and 18S RNA (gel
photo) is also shown. This is a representative experiment independently performed four times.
Further analysis revealed that PRL and pig GH resulted in an equivalent level of STAT5
phosphorylation (Figure 2.4). Human GH was also capable of activating STAT5 to a lesser
extent, yet did not have any effect on PDK4 (Figure 2.3). Interestingly, all of the hormones
resulted in equivalent levels of extracellular signal-related kinase (ERK) 1 and 2 (active MAPK)
activation.
To further examine the specificity of the induction of PDK4, we examined the effects of
several STAT1 and STAT3 activators. We have previously shown that these cytokines are potent
activators of STAT1 or STAT3 or both of these STATs in 3T3-L1 adipocytes, but do not activate
STAT5 proteins (154;169). Total RNA was isolated from serum deprived 3T3-L1 adipocytes
after a 2-h treatment with ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), leukemia
inhibitory factor (LIF), interferon γ (IFNγ), or PRL. As shown in Figure 2.5, we observed that
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Figure 2.4 Prolactin, porcine Growth Hormone, and human Growth Hormone activate STAT 5 in
3T3-L1 adipocytes. From the same group of cells, whole cell extracts were isolated after a 15
minute treatment with the same doses of the hormone listed above. Twenty-five μg of protein
from each sample was subjected to SDS-PAGE, and then were transferred to nitrocellulose for
immunoblot analysis. This is a representative experiment independently performed four times.
PRL, but not any of the other cytokines, induced PDK4 expression. β-actin is included as a
loading control. The efficacy of the cytokines was confirmed by examining STAT activation
(data not shown).
Because previous studies suggest that insulin has the ability to suppress PDK4 expression
in other tissues (183-185), we examined the PRL- and GH-mediated induction of PDK4 mRNA
after an insulin pretreatment in adipose tissue. Fully differentiated 3T3-L1 adipocytes were
treated with porcine GH or PRL for 2 hours in the presence or absence of a 20 minute insulin
pretreatment. The robust activation of PDK4 mRNA following the treatment with either PRL or
GH was evident with no insulin pre-incubation; but the induction of PDK4 mRNA was
substantially attenuated by the insulin pretreatment (Figure 2.6).
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Figure 2.5 STAT1 and STAT 3 activators do not induce PDK4 expression in 3T3-L1 adipocytes.
Total RNA was isolated from serum deprived 3T3-L1 adipocytes following 2 nM ciliary
neurotrophic factor (CNTF), 0.2 nM cardiotrophin-1 (CT-1), 0.5 nM leukemia inhibitory factor
(LIF), 100 U/ml interferon γ (IFNγ), or 0.5 nM prolactin treatment. Untreated cells (CTL) were
also harvested at the start of the experiment. Fifteen μg of total RNA was subjected to Northern
blot analysis. This is a representative experiment independently performed two times.

Figure 2.6 The induction of PDK4 by prolactin or growth hormone is attenuated by insulin
pretreatment in 3T3-L1 adipocytes. Total RNA was isolated from serum deprived 3T3-L1
adipocytes following 2 hour treatments with 0.5 nM porcine GH or 0.5 nM PRL in the presence
or absence of a 20 minute 50 nM insulin pretreatment. Fifteen μg of total RNA was subjected to
Northern blot analysis. This is a representative experiment independently performed three times.

33

Because PRL and GH are potent activators of STAT5, we searched the murine PDK4
promoter for STAT binding motifs in the promoter region 2.5 kb upstream of the transcription
start sites. Typically, STAT proteins bind a core palindromic sequence, TTC NNN GAA, and
selective variation can occur in particular nucleotide positions (190). One consensus STAT
binding motif was identified at -389 in the PDK4 promoter. An oligonucleotide probe containing
9-bp of the core STAT motif with 6-bp of flanking sequence on either end was incubated with
cytoplasmic or nuclear extracts from PRL treated 3T3-L1 adipocytes. To evaluate this potential
STAT5 binding site, we performed electrophoretic mobility shift assays (EMSAs). As shown in
Figure 2.7, we observed PRL-induced binding when the labeled probe was incubated with
nuclear extracts from PRL treated adipocytes. Specific binding to the probe was also confirmed
by results demonstrating that cytosolic proteins did not bind to this site and pre-incubation with
unlabeled probe decreased binding intensity (Figure 2.7, last lane).
Pre-incubation of nuclear extracts with specific antibodies to individual STAT proteins in
a supershift EMSA indicated that STAT5A was present in the binding complex induced by PRL
(Figure 2.8). In addition, STAT1 and STAT3 did not participate in binding to the STAT element
in the PDK4 promoter. Our data clearly demonstrate that the -389 to -378 region of the murine
PDK4 promoter binds nuclear PRL-activated STAT5A proteins in vitro.
To determine whether this region of the PDK4 promoter contributed to the regulation of
PDK4 by STAT5 activators in living cells, we performed site-specific mutagenesis to alter two
bp within the murine PDK4 promoter/luciferase construct. We have shown that this mutation
abolished binding of PRL-induced proteins to this site (data not shown). Transfection of the
wild-type and mutant constructs into 3T3-L1 cells revealed that the basal level of luciferase
activity was not significantly affected by mutation of the STAT5A site that we identified in the
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Figure 2.7 Prolactin induces binding to a potential STAT site at -389 to -378 of the mouse PDK4
promoter in vitro. Cytosolic and nuclear extracts were prepared from differentiated serum
deprived 3T3-L1 adipocytes that were untreated or treated with PRL for 15 min. For each
sample, 10 μg of protein were incubated with 50,000 cpm/ml of a -389 to 378 32P-labeled probe
of the murine PDK4 promoter. The protein-DNA complexes were resolved by EMSA. For cold
competition, nuclear extracts were preincubated with an excess of the indicated unlabeled
oligonucleotides (10 μM). The PRL-sensitive shift is indicated with an arrow. This is a
representative experiment independently performed three times.
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Figure 2.8 STAT 5A, but not STATs 1 or 3, was present in the binding complex induced by
Prolactin in vitro. Cytosolic and nuclear extracts were prepared from 3T3-L1 adipocytes treated
with PRL for 15 min. For supershift analysis, 10 μg of protein were preincubated with 4 μg of
the indicated antibody and then incubated with 50,000 cpm/ml of the indicated 32P-labeled probe
of the -389 to -378 site in the mouse PDK4 promoter. The protein-DNA complexes were
resolved by EMSA. This is a representative experiment independently performed two times.
PDK4 promoter (Figure 2.9). In addition, a 2-4 fold increase in luciferase activity was observed
following a 2 hour PRL or GH (porcine) treatment and measurement of the wild-type construct.
In addition, the construct containing the mutated STAT5 site was unresponsive to induction by
GH or PRL. Thus, these data clearly indicate that the -389 to -378 site of the PDK4 promoter is
sensitive to GH and PRL, and these data also suggest that this site confers the positive regulation
of PDK4 by GH- and PRL-activated STAT5A protein complexes.
The expression and modulation of PDK4 in skeletal muscle is well documented, yet, the
induction of PDK4 in adipocytes has not been previously observed. Because our studies indicate
that PRL increased PDK4 mRNA levels, we hypothesized that PDK4 protein levels might be
increased following PRL treatment. Hence, we exposed fully differentiated serum deprived 3T336

Figure 2.9 Prolactin and growth hormone induce the activity of the mouse PDK4 promoter in
3T3-L1 cells via a STAT5 binding site. Proliferating 3T3-L1 cells were transiently transfected
with murine PDK4 promoter (-949 to +24)/luciferase constructs (wildtype or mutant) and the
TK/renilla vector to control for transfection efficiency. After 48 hours of transfection, cells were
stimulated with PRL or GH for two hours. Relative light units (RLU) were calculated by
dividing firefly luciferase activity by renilla luciferase activity. Results are shown as +/- standard
deviation. For each experiment, three plates of cells were used for each particular condition. In
addition, each experiment was performed in triplicate on three independent batches of cells with
similar results.
L1 adipocytes to PRL and isolated whole cell extracts to examine PDK4 expression. Chronic
treatments (22 hours or more) did not result in any substantial changes in PDK4 protein levels
(data not shown). Since the effects of STATs on gene expression are usually transient, we
examined the ability of shorter PRL treatments to modulate PDK4 expression. As shown in
Figure 2.10, we observed a significant induction of PDK4 protein levels following a 6 and 8 hour
treatment with PRL. After 24 hours, this induction was not substantial. We did observe some
fluctuation in the time in which prolactin-induced levels of PDK4 protein. In some experiments,
we observed a substantial induction at 4 hours whereas in most experiments, the levels of PDK4
protein were the greatest after an 8-10 hour treatment. However, in all of our experiments, there
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was no significant effect observed after a 22 hour PRL treatment. The efficacy of the PRL
treatment was demonstrated by showing the activation of STAT5 and ERKs 1 and 2 (active
MAPK).
Because PRL induced PDK4 proteins levels, we hypothesized that glucose uptake might
be regulated under these conditions. The results in Figure 2.11 demonstrate that a 10 minute
treatment with insulin results in a fivefold increase in glucose uptake in fully differentiated 3T3L1 adipocytes. Also, a 6 hour treatment with PRL resulted in a substantial decrease (2.5 fold) in
insulin-stimulated glucose uptake. The induction of PDK4 protein under these conditions was
confirmed by Western Blot analysis (data not shown).

Figure 2.10 Prolactin induces the expression of PDK4 protein in 3T3-L1 adipocytes in a time
dependent manner. Fully differentiated 3T3-L1 adipocytes were serum deprived overnight and
then exposed to prolactin for the times indicated. One hundred μg of protein from whole cell
extracts were loaded into the gel for each sample. The samples were subjected to SDS-PAGE,
and then were transferred to nitrocellulose for immunoblot analysis. This is a representative
experiment independently performed four times.
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Figure 2.11 The effects of PRL on insulin stimulated glucose uptake in 3T3-L1 adipocytes.
Serum deprived, fully differentiated 3T3-L1 adipocytes were untreated or incubated with 0.5 nM
PRL for 6 hours. Cells were then exposed to 50 nM insulin or saline control for 10 minutes.
Glucose uptake was measured as described in Experimental Procedures. Values shown represent
the mean +/- S.E. (light bars = saline control, dark bars = insulin treatment) of triplicate
determinations from four independent experiments.
2.4 Discussion
The novel findings in this study include data demonstrating that PDK4 levels are induced
in adipocytes after stimulation with two STAT5 activating hormones, the identification of a
hormone responsive region in the murine PDK4 promoter, and the characterization of a STAT5
binding site in this region. These results strongly suggest that STAT5A directly activates the
expression of PDK4 in adipocytes. Moreover, our data indicate that PRL and STAT5A could
induce conditions of insulin resistance by inducing PDK4 expression and attenuating insulinstimulated glucose uptake.
Although GH is a well-known modulator of metabolism and is a known affector of
insulin action (reviewed in (172))(191), the role of PRL in these processes is less understood.
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PRL is primarily a pituitary secreted hormone, yet in humans, PRL is produced and secreted
from additional tissues, such as human glandular and adipose breast tissues (192), and human
deciduas (193), and is a circulating hormone (reviewed in (194)). The presence of PRL receptors
in almost all organs, including adipocytes (131), contributes to prolactin’s diverse roles.
Recently, a novel human adipocyte cell line, LS14, has been developed that produces and
responds to PRL (195).

In morbidly obese patients, the amount of PRL secreted from

subcutaneous adipose tissue is much less than in lean patients, but, surprisingly, there are no
apparent differences in PRL secretion between men and women (reviewed in (194)).
Studies have also implicated PRL as a contributor to insulin resistance. One study
conducted in lean pregnant women demonstrated that PRL could cause insulin resistance in
adipocytes by suppressing adiponectin production and secretion (196).

This mechanism is

plausible, because low levels of adiponectin can be associated with obesity and insulin
resistance. Although the crosstalk between PRL and leptin action is not well understood, PRL
has been shown to suppress insulin-induced leptin secretion in cultured adipocytes (197). PRL
also decreases insulin-stimulated glucose uptake in pregnant rat adipose tissue (198). Likewise,
severe hyperprolactinemia has been shown to induce an insulin-resistant state by decreasing
insulin binding in human subjects (199). Our data presents another plausible mechanism by
which PRL may cause insulin resistance in adipocytes by modulating PDK4 levels.
Previous studies support similar or overlapping functions for PRL and GH in mammary
gland metabolism (200). Our studies revealed that sheep PRL and porcine GH behaved similarly
to modulate PDK4 levels in murine adipocytes. As is commonly known for PRL action, we
observed a bell-shaped curve rather than linear dose-dependence relationship, and higher doses
of the hormone were inhibitory. Interestingly, human GH had no substantial effects on PDK4,
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despite its ability to weakly activate STAT5A and strongly activate ERKs 1 and 2. In multiple
independent experiments, we demonstrated the induction of PDK4 by sheep PRL and porcine
GH, but not human GH in 3T3-L1 adipocytes. This data is intriguing, since human GH did
result in some activation of STAT5A, but did not induce PDK4 levels. A BLAST analyses
revealed that human GH and mouse GH have a 69.7% similarity (58.3% identity). However,
porcine GH and mouse GH have a 94.4% similarity (89.8% identity). Hence, we hypothesize that
the human GH does not engage the murine receptor normally due to the substantial difference in
homology. Alternatively, the activation of STAT5 by sheep PRL and porcine GH may include an
additional factor(s) that participates in the induction of PDK4 expression, and this factor is not
similarly modulated by human GH signaling in murine adipocytes.
Although it has been shown that insulin has the ability to suppress PDK4 expression in
various other tissues (183-185), our studies demonstrate that insulin has the ability to suppress
the PRL- and GH- induced PDK4 expression in adipocytes. Because the basal levels of PDK4
are low in adipocytes, we did not observe a strong repression of PDK4 mRNA following insulin
treatment alone (Figure 2.6). Our studies provide evidence to support antagonistic cross-talk
between PRL or GH and insulin, as well as the possible role of PRL in insulin resistance in
adipose tissue. In addition, our results indicate that a 6 hour PRL treatment results in an
inhibition of insulin-sensitive glucose uptake. This data is complemented by studies showing that
reduced PDK4 expression is associated with increased insulin sensitivity (186). In summary, the
presence of PDK4 protein in adipocytes correlates with an attenuation of insulin-sensitive
glucose uptake and likely plays a role in the ability of prolactin to induce insulin resistance.
Studies have shown that other transcription factors, such as FOXO, also bind to the
PDK4 promoter and induce PDK4 expression in response to starvation in the skeletal muscle of
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mice (201). Glucocorticoids, which are implicated in insulin resistance, also increase the
expression of PDK4, and insulin antagonizes these effects (185). Additional studies show that
insulin suppresses the PDK4 induction mediated by glucocorticoids by inactivation of FOXO
transcription factors, which are required for full transcriptional activation of the PDK4 gene by
glucocorticoids (202).

The transcriptional co-activator peroxisome proliferator-activated γ

coactivator (PGC)1α has also been shown to induce the expression of PDK4 in primary rat
hepatocytes and ventricular myocytes (203).

In C2C12 myoblasts, PGC1α induces PDK4

expression in a manner that is dependent on ERRα (204). Hence, in muscle, the modulation of
PDK4 can be influenced by FOXO transcription factors and PGC1α. Our studies demonstrate a
novel induction of PDK4 in adipocytes that is mediated by a STAT 5A binding site in the
mPDK4 promoter. Other studies from our laboratory have shown that adipocyte STAT 5A can
inhibit the expression of fatty acid synthase (FAS) (153) and bind to the promoter of the acyl CoA oxidase (AOX) gene, which correlates with an increase in AOX expression (151). Hence, the
role of STAT5A in mature adipocytes appears to be one that attenuates lipid accumulation and
favors lipid oxidation. Interestingly, our studies on PDK4 also suggest that STAT 5A may
contribute to energy homeostasis by decreasing glucose oxidation and increasing insulin
resistance in adipocytes. The differential capabilities of STAT 5A are apparent from several
studies that demonstrate that in various preadipocytes or non-precursor cells that STAT5A can
promote lipid accumulation and adipogenesis (144-146). Although the mechanisms that account
for the ability of STAT 5A to have lipogenic or lipolytic effects have not been clearly defined,
collectively these studies indicate that STAT 5A is likely an important contributor to
maintenance of energy balance, particularly in response to hormones.
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Because PDK inhibitors have been shown to be effective potential therapeutics in
improving glycemic control and type 2 diabetes (reviewed in (205)), these kinases warrant more
in-depth analysis. In particular, PDK4 proves to be an object of necessary consideration because
it is expressed in substantial amounts in skeletal muscle and adipose tissue. We have observed
that PRL and GH can induce the expression of PDK4 in adipocytes and positively regulate the
murine PDK4 promoter. Our identification of a STAT5 binding site in the promoter of PDK4
characterizes a novel mechanism of regulating its expression. In summary, we hypothesize that
the regulation of PDK4 by PRL and GH via STAT 5A is likely an important contribution to the
maintenance of energy homeostasis.
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CHAPTER 3
NEUROPOIETIN ATTENUATES ADIPOGENESIS AND INDUCES INSULIN
RESISTANCE IN ADIPOCYTES2
3.1 Introduction
In recent years, gp130 receptor ligands, notably ciliary neurotrophic factor (CNTF), have
been implicated as potential targets for obesity therapeutics (reviewed in (162)). It is well known
that obese individuals are usually leptin resistant, despite increased production of endogenous
leptin (40)(reviewed in (206). Hence, leptin is not a viable cytokine therapeutic. Therefore, the
characterization of cytokine-mediated anti-obesity mechanisms that act independently of leptin
may be utilized for the treatment of obesity. Because gp130 and leptin receptor (LRβ) possess
substantial sequence homology (207;208) and both activate the JAK/STAT pathway (209) and
other signal transduction pathways that are important in energy balance (210-213), gp130
cytokines may provide a mechanism to evade leptin resistance. Also, recent studies have shown
that CNTF can have anti-obesogenic effects in both high fat diet induced and db/db mice (214),
indicating that the effects of CNTF are not dependent on a functional leptin receptor. In
addition, leptin does not stimulate the tyrosine phosphorylation of gp130 to activate the
JAK/STAT pathway (209). These data suggest that neither gp130 nor LRβ signal through each
other’s ligand. Likewise, the efficacy of the gp130 cytokine as a therapeutic would not be
altered due to the leptin resistant phenotype.
CNTF was originally characterized through its ability to maintain the survival of
parasympathetic and motor neurons (reviewed in (215)). The anti-obesogenic properties of
CNTF were discovered in clinical trials examining its effects on progression of the
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neurodegenerative disease amyotrophic lateral sclerosis (216). This observation led to many
studies to understand the effects of CNTF on weight-loss. Early studies revealed that the CNTF
receptors and LRβ were colocalized in the hypothalamus, and CNTF administration activated or
suppressed the same genes as leptin in the arcuate nucleus (217). These studies suggested
similar roles for these cytokines in neuronal signaling pathways that affect satiety. Also, CNTF
treatment of leptin-deficient ob/ob and leptin-resistant db/db mice as well as mice with dietinduced obesity and partial resistance to leptin was found to reduce adiposity, hyperphagia, and
hyperinsulinemia (217). Subsequent studies revealed that Axokine, a human recombinant form
of CNTF, also improved the phenotype of obese, leptin resistant rodents (218). Collectively,
these studies provide evidence to support the use of gp130 cytokines, specifically CNTF, as
potential obesity therapeutics.
Though all gp130 cytokines share the transmembrane protein gp130 as a transducer in
their receptor complex (reviewed in (157), the other components of each respective complex are
variable. Interleukin-6 (IL-6) and interleukin-11 (IL-11) first bind to IL-6 receptor α and IL-11
receptor α, respectively, and then recruit a gp130 homodimer complex for signaling. Interleukin27 (IL-27) engages a gp130/WSX-1 heterodimeric receptor complex (155). Leukemia inhibitory
factor (LIF) and oncostatin M (OSM) directly bind the gp130/LIF receptor (LIFR) complex to
induce signal transduction; OSM can alternatively utilize a gp130/OSM receptor (OSMR)
complex. Cardiotrophin-1 (CT-1) recruits an alpha receptor (159), which to date has not been
characterized, and also signals via gp130/LIFR. CNTF, cardiotrophin-like-cytokine (CLC), and
neuropoietin (NP) all recruit CNTFRα and then induce the formation of a gp130/LIFR
heterodimer for signal transduction (156;160;161). The requirement of NP to utilize CNTF

45

signaling receptors was supported by studies which showed that NP did not signal in cells
expressing only LIFR and gp130, but not CNTFRα (156).
CNTF-deficient mice develop normally and exhibit only a mild loss of motor neurons
later in adulthood (219), whereas newborn mice lacking CNTFRα display a dramatic loss of
motor neurons, fail to initiate the feeding process, and die shortly after birth (220). These studies
provided evidence for the existence of an alternative ligand for the CNTF receptor complex
which led to the initial characterization of NP, a 22 kDa member of the gp130 cytokine family
(156). Though not detected in adult tissues, NP is expressed in embryonic mouse neuroepithelia
at a time during development when both CNTF and CLC are absent (156). NP, like CNTF, can
also mediate motor neuron survival (156). Importantly, the actions of NP are dependent on the
presence of the tripartite functional receptor complex for CNTF that includes CNTFRα, LIFR
and gp130 (156;160). Due to the functional similarities between NP and CNTF and their
utilization of the same tripartite receptor complex, we hypothesized that NP might mimic the
anti-obesogenic properties of CNTF. We have previously shown that CNTF treatment induces
STAT3 activation in adipocytes in vitro and in vivo and that CNTFRα is expressed in adipose
tissue and regulated in obese/type II diabetic rats (165).
Because CNTF induces weight loss (216-218) and does not result in the development of
insulin resistance in adipocytes (165) and NP utilizes the same tripartite receptor complex as
CNTF (156), we examined the ability of NP to modulate adipocyte differentiation and insulin
action. Although the roles of NP in the nervous system have been examined, the effects of NP
on adipocytes have not been studied. Our results demonstrate that both 3T3-L1 adipocytes and
rat adipose tissue are responsive to NP treatment. Our studies also indicate that NP specifically
activates STAT3 Tyr705 in vivo and in vitro. We also observed the induction of SOCS-3 mRNA
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in 3T3-L1 adipocytes and MAPK (ERK 1 and 2) activation in vivo following NP treatment. In
addition, our studies demonstrate that NP can inhibit adipogenesis and negatively affect insulin
signaling in cultured adipocytes.

Overall, our findings indicate that adipocytes are highly

responsive to NP. However, unlike CNTF, our results indicate that NP is not a suitable antiobesity therapeutic since it inhibits insulin action in adipocytes.
3.2 Materials and Methods
Materials – Dulbecco’s Modified Eagle’s Media (DMEM) was purchased from Sigma. Bovine
and fetal bovine (FBS) sera were purchased from Atlanta Biological. Mouse recombinant NP,
mouse recombinant CT-1, mouse recombinant OSM, and rat recombinant CNTF were all
purchased from R&D Systems. Mouse recombinant LIF was purchased from BD Transduction.
GH (porcine) and insulin (bovine) were purchased from Sigma. STAT1 and STAT5A were
polyclonal IgGs purchased from Santa Cruz. STAT3 was a monoclonal IgG purchased from BD
Transduction. The phospho-specific monoclonal antibody for STAT3 (Y705) was purchased from
BD Transduction. The highly phospho-specific polyclonal antibodies for IRS1 (Y896) and Akt
(S473) were purchased from Biosource and Cell Signaling, respectively. The ERK polyclonal
antibody and the PPARγ monoclonal antibody were both purchased from Santa Cruz. The
polyclonal Active MAPK antibody was purchased from Promega.

Adiponectin polyclonal

antibody was purchased from Affinity Bioreagents. DNase I and Trizol were both purchased
from Invitrogen. Nitrocellulose and Zeta Probe-GT membranes were purchased from Bio-Rad.
The BCA kit and the enhanced chemiluminescence kit were purchased form Pierce. Horseradish
peroxidase

(HRP)-conjugated

secondary

antibodies

ImmunoResearch Laboratories.
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were

purchased

from

Jackson

Cell Culture – Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence
in DMEM containing 10% bovine serum. Medium was changed every 48 h. Cells were induced
to differentiate by changing the medium to DMEM containing 10% fetal bovine serum (FBS),
0.5 mM 3-isobutylmethylxanthine, 1 μM dexamethasone, and 1.7 μM insulin (MDI). After 48 h,
this medium was replaced with DMEM supplemented with 10% FBS and cells were maintained
in this medium until utilized for experimentation. In some experiments, cells were induced to
differentiate in the presence of NP and treated at various times after the addition of the
differentiation cocktail.
Preparation of Whole Cell Extracts – Cell monolayers of 3T3-L1 adipocytes were harvested in
a non-denaturing buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM
EDTA, 1% Triton-X 100, 0.5% Igepal CA-630, 1 μM phenylmethylsulfonyl fluoride (PMSF), 1
μM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium
vanadate and frozen. Next, the samples were thawed and centrifuged at 13,000 rpm at 4oC for 10
minutes. Supernatants containing whole cell extracts were analyzed for protein content using a
BCA kit according to the manufacturer’s instructions.
Preparation of Nuclear and Cytosolic Extracts – Untreated and NP treated serum deprived
3T3-L1 adipocytes were harvested in a nuclear homogenization buffer containing 20 mM Tris
(pH 7.4), 10 mM NaCl, and 3 mM MgCl2. Igepal CA-630 was added to a final concentration of
0.15%, and cells were homogenized with 16 strokes in a Dounce homogenizer.

The

homogenates were centrifuged at 10000 x g for 8 min. Supernatants were saved as cytosolic
extract, and the nuclear pellets were resuspended in half the volume of nuclear homogenization
buffer and were centrifuged as before. The pellet was then resuspended in an extraction buffer
containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 25%
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glycerol. Both cytosolic and nuclear samples were frozen until time for analysis and later
thawed at room temperature. Two hundred units of DNase I was added to each nuclear sample
and the tubes were inverted and incubated an additional 10 min at room temperature. Finally, the
samples were subjected to centrifugation at 10,000 x g at 4oC for 10 minutes. Cytosolic fractions
and supernatants containing nuclear extracts were analyzed for protein content using a BCA kit
(Pierce).
Rodent Adipose Tissue Isolation – Animals were euthanized by cervical dislocation, and
tissues were immediately removed and frozen in liquid nitrogen. Frozen tissues were
homogenized in a buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1mM EGTA, 1mM
EDTA, 1% Triton-X 100, 0.5% Igepal CA-630, 1 μM PMSF, 1 μM pepstatin, and 50 trypsin
inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium vanadate. Homogenates
were centrifuged for 10 minutes at 1000 x g to remove any debris and insoluble material and
then analyzed for protein content. All animal studies were carried out with protocols which were
reviewed and approved by institutional animal care and use committees.
Gel Electrophoresis and Western Blot Analysis – Proteins were separated in 7.5%
polyacrylamide (acrylamide from National Diagnostics) gels containing sodium dodecyl sulfate
(SDS) according to Laemmli (187) and transferred to nitrocellulose membrane in 25 mM Tris,
192 mM glycine, and 20% methanol. Following transfer, the membrane was blocked overnight
in 4% milk at 4oC. Results were visualized with horseradish peroxidase (HRP)-conjugated
secondary antibodies and enhanced chemiluminescence.
RNA Analysis – Total RNA was isolated from cell monolayers with Trizol according to the
manufacturer’s instructions with minor modifications. For Northern blot analysis, 20 μg of total
RNA was denatured in formamide and electrophoresed through a formaldehyde/agarose gel.
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The RNA was transferred to Zeta Probe-GT, cross-linked, hybridized, and washed as previously
described (43). Probes were labeled by random priming using Klenow fragment and [α
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P]

dATP.
Determination of 3H-labeled 2-Deoxyglucose Uptake – The assay of 2- [3H] deoxyglucose was
performed as previously described (189). Prior to the assay, mature 3T3-L1 adipocytes were
serum deprived for 2 h and then incubated in the presence or absence of insulin (50 nM) for 10
min and the presence or absence of NP for 6h. Glucose uptake was initiated by addition of 2[3H] deoxyglucose at a concentration of 0.1 mM 2-deoxyglucose in 1 μCi 2- [3H] deoxyglucose
in Krebs-Ringer-Hepes buffer and incubated for 3 min at room temperature. Glucose uptake is
reported as [3H] radioactivity, corrected for nonspecific diffusion (5 μM cytochalasin B) and
normalized to total protein content as determined by BCA analysis. Nonspecific uptake and
absorption was always less than 10% of the total uptake. Uptake measurements were performed
in triplicate under conditions where hexose uptake was linear.
3.3 Results
To determine if adipocytes were responsive to NP, we examined the ability of this gp130
cytokine to activate STAT proteins in adipocytes. Fully differentiated 3T3-L1 adipocytes were
treated with several different gp130 cytokines including CT-1, LIF, OSM, and NP for 10
minutes. As shown in Figure 3.1, NP activated STAT3 Tyr705 phosphorylation in a manner
equivalent to CT-1, LIF, and OSM. Because growth hormone (GH) is not a gp130 cytokine and
is not a potent activator of STAT3 tyrosine phosphorylation in these cells (164), this growth
factor was used as a negative control. The levels of STAT3 protein were equivalent in each
sample.
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Figure 3.1 Neuropoietin activates STAT3 as potently as other gp130 cytokines. Fully
differentiated 3T3-L1 adipocytes were treated for 10 min with either CT-1(1 nM), LIF (1 nM),
OSM (1 nM), NP (1 nM), or GH (.5 nM). Following the treatment, whole cell extracts were
prepared, and one hundred fifty μg of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. The detection system was HRPconjugated secondary antibodies and enhanced chemiluminescence. This is a representative
experiment independently performed three times.
To investigate the specificity of NP action in adipocytes, serum-deprived fully
differentiated 3T3-L1 adipocytes were treated with various doses of NP (0.12 nM, 0.25 nM, 0.5
nM, 1 nM, 2 nM, and 2.5 nM) or insulin for 10 min. Although we detected low levels of STAT3
activation with 0.25 nM and 0.5 nM NP, we observed substantial activation with 1 nM, 2 nM,
and 2.5 nM NP treatments (Figure 3.2). These results indicate that NP activated STAT3 Tyr705
in a dose-dependent manner, with maximal activation at 1 nM.

Figure 3.2 Neuropoietin activates STAT3 in a dose-dependent manner. Fully differentiated 3T3L1 adipocytes were treated for 10 min with the various doses of NP or Insulin (50 nM).
Following the treatment, whole cell extracts were prepared, and one hundred fifty μg of each
extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.
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Because insulin induces the serine, but not the tyrosine, phosphorylation of STAT3 (164;221),
this peptide hormone was used as a negative control. ERK (MAPK) protein levels are shown to
demonstrate even loading.
Previous studies have demonstrated that, in addition to STAT3, STATs 1, 5A, 5B, and 6
are expressed in both cultured and native adipocytes (139). Therefore, we examined the ability
of NP to activate other adipocyte expressed STATs. Fully differentiated 3T3-L1 adipocytes
were treated with NP for different times, ranging from 0.3 to 5 h. The cells were homogenized
and fractionated into nuclear and cytosolic extracts. The activation of STATs was observed by
examining the presence of these proteins in the nucleus. Based on the results in Figure 3.3, NP
did not activate STATs 1 and 5A, as the levels of these STATs in the nucleus of NP treated cells
were similar to untreated control cells.

In contrast, we observed a robust time dependent

activation and nuclear translocation of STAT3.
Because various members of the gp130 cytokine family are known to induce Suppressors
of Cytokine Signaling (SOCS)-3 (222), we examined the ability of NP to induce SOCS-3
expression in fully differentiated 3T3-L1 adipocytes. As shown in Figure 3.4, NP treatment
resulted in a transient induction of SOCS-3 mRNA that was detectable at 30 minutes and
maximum expression occurred after a 1 hr treatment. Both aP2 and β-actin mRNA levels were
unaffected by the NP treatments. Ribosomal RNAs are shown to demonstrate even loading of
total RNA.
The data in Figures 3.1-3.4 clearly indicated that NP activates STAT3 and SOCS-3 in
adipocytes in vitro; hence, we wanted to determine if adipocytes in vivo were responsive to NP.
Sprague Dawley rats were injected with either NP (0.20 μg/g animal) or vehicle (saline) and then
sacrificed 15 minutes following the injection. As shown in Figure 3.5, NP injection induced the
52

Figure 3.3 Neuropoietin induces the translocation of STAT3 to the nucleus. Cytosolic and
nuclear extracts were prepared from fully differentiated 3T3-L1 adipocytes following a treatment
with 1 nM NP for the times indicated. One hundred fifty μg of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Each figure
represents an experiment independently performed three times.
activation of STAT3 Tyr705 in both the epididymal and retroperitoneal adipose tissues, but not in
skeletal muscle. NP also induced the activation of MAPK (ERKs 1 and 2) in adipose tissue, but
not skeletal muscle. The inability of NP to induce STAT3 tyrosine phosphorylation in skeletal
muscle was not due to decreased levels of STAT3 expression.
Since gp130 cytokines have been reported to have differential effects on adipogenesis
(166;168;223), we investigated the ability of NP to modulate adipocyte differentiation. As
shown in Figure 3.6, 3T3-L1 preadipocytes were induced to differentiate in the presence or
absence of exogenously added NP and whole cell extracts were harvested at the indicated time
points. Adipogenesis was assessed by examining the induction of PPARγ and adiponectin. NP
attenuated adipogenesis, as evidenced by the decrease in expression of both PPARγ and
adiponectin at 72 h and 96 h after the induction of differentiation.
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Figure 3.4 Neuropoietin induces SOCS-3 mRNA. Fully differentiated 3T3-L1 adipocytes were
treated with 1 nM NP for the times indicated. Following the treatment total RNA was collected
from the cells and twenty μg of each total RNA was electrophoresed, transferred to nylon, and
subjected to Northern blot analysis. This is a representative experiment independently performed
three times.

Figure 3.5 Neuropoietin induces STAT3 tyrosine phosphorylation in adipose tissue in vivo. Six
week old male Sprague Dawley rats were given an intraperitoneal injection of NP (0.20 μg/g
animal) or vehicle (saline) control. In each individual experiment, at least two animals were
used for each condition. Fifteen minutes after the injection the rats were sacrificed and both
retroperitoneal and epididymal fat pads and skeletal muscle tissues were immediately removed
and frozen in liquid nitrogen. Two hundred fifty μg of each tissue extract was separated by SDSPAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a
representative experiment independently performed three times.
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Figure 3.6 Neuropoietin attenuates the differentiation of 3T3-L1 adipocytes. Whole cell extracts
were prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to differentiate in the
presence (+) or absence (-) of NP (1 nM). Cells were treated every 24 h with a fresh bolus of
NP. Two hundred μg of each sample was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis.
We also examined the ability of NP to modulate adipogenesis in the absence of insulin.
The preadipocytes were induced to differentiate with normal differentiation media (MDI) or
media minus insulin (MD) and harvested 96 h post induction. As shown in Figure 3.7, NP was
capable of blocking the induction of both PPARγ and adiponectin without insulin present in the
induction cocktail. Because cells treated with MD media exhibited less differentiation, we used
a greater protein concentration than in the normally differentiated cells.
To compare the effect of NP to other gp130 cytokines, 3T3-L1 preadipocytes were
induced to differentiate in the presence of NP, as well as CNTF, CT-1, OSM, and GH. As
shown in Figure 3.8, both NP and OSM greatly attenuated adipogenesis as shown by the
decreased expression of PPARγ and adiponectin, while CNTF and CT-1 had no effect on
adipocyte marker expression and was similar to untreated cells. We have previously shown that
CT-1 (166) and CNTF (165) do not inhibit adipogenesis. These results also confirm recent
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studies showing that OSM can inhibit murine (223) and human (224) adipocyte differentiation.
It is also known that GH does not affect the adipogenesis of 3T3-L1 cells (225). STAT3
expression does not change during adipogenesis of murine (142) or human (140) cells and was
used as a loading control.

Figure 3.7 Neuropoietin attenuates the differentiation of 3T3-L1 adipocytes in the presence or
absence of insulin. 3T3-L1 cells were induced to differentiate in the presence (+) or absence (-)
of NP (1 nM). Cells were treated every 24 h with a fresh bolus of NP. Two samples were
induced to differentiate with normal (MDI) cocktail, while the other samples were induced with
differentiation cocktail minus insulin (MD). Whole cell extracts were harvested 96 h after the
induction of differentiation. Ninety μg of samples with normal MDI and two hundred μg of
samples with MD media were subjected to Western blot analysis. This is a representative
experiment independently performed three times.
To demonstrate the specificity of the ability of NP to negatively affect adipogenesis, we
investigated whether the attenuation was dose and time dependent. In Figure 3.9, 3T3-L1
preadipocytes were induced to differentiate in the presence of NP at the various doses indicated
and harvested 4 days after the induction of adipogenesis. Cells were treated every 24 h with a
fresh bolus of NP. Although there were no changes in protein expression at .25 nM NP, we
observed a decrease in PPARγ and adiponectin expression at 0.5 nM, with the greatest
attenuation of adiponectin at 1 nM and PPARγ at 2 nM.
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Figure 3.8 Neuropoietin and Oncostatin M attenuate the differentiation of 3T3-L1 adipocytes
Whole cell extracts were prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to
differentiate in the presence of either NP (1 nM), CNTF (1 nM), CT-1 (1 nM), OSM (1 nM), or
GH (0.5 nM). Cells were treated every 24 h with a fresh bolus of each specific cytokine or
growth factor. Two hundred μg of each sample was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. Each figure represents an experiment
independently performed at least three times.
In Figure 3.10, 3T3-L1 preadipocytes were induced to differentiate in the presence of NP
at different times post the induction of adipogenesis. Cells were treated every 24 h with a fresh
bolus of NP after their initial treatment. Our data indicated that a decrease in expression of
adipogenic markers occurred when NP was added between 0 h and 48 h post induction. When
NP was added 72 h or 96 h post induction, we did not observe a change in PPARγ or adiponectin
levels. The efficacy of NP was assessed by examining the activation of STAT3 Tyr705, and
STAT3 protein levels were observed to demonstrate even loading in both experiments.
Because other gp130 cytokines have been reported to have effects on insulin signaling,
we examined how NP affects insulin action.

As shown in Figure 3.11, mature 3T3-L1

adipocytes were pretreated with NP (+) for the times indicated, and then exposed to an acute 10
min treatment of insulin. As expected, a 10 min insulin treatment resulted in the activation of
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Figure 3.9 Neuropoietin inhibits adipogenesis in a dose dependent manner. Whole cell extracts
were prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to differentiate in the
presence of NP at the various doses indicated. Cells were treated every 24 h with a fresh bolus
of NP. One hundred fifty μg of each sample was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis.
IRS-1 Tyr896 and Akt Ser473, which are substrates and indicators of insulin signaling. However,
pretreatment with NP prior to insulin stimulation resulted in a decrease in IRS-1 Tyr896 signaling
at 10 min, and we observed this inhibition with each NP pretreatment. Although we did not see a
decrease in Akt Ser473 signaling after the 10 min NP pretreatment, we observed a significant
attenuation in Akt activation after 2 hrs with NP pretreatment. The efficacy of the NP was
demonstrated by confirming the activation of STAT3 Tyr705. A longer exposure of the film
revealed lower levels of STAT3 phosphorylation following longer NP pretreatment. ERK
(MAPK) protein levels were examined to demonstrate even loading.
Because NP negatively affects insulin signaling in adipocytes, we examined the effects of
NP on insulin signaling in preadipocytes. As shown in Figure 3.12, confluent 3T3-L1
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Figure 3.10 Neuropoietin inhibits adipogenesis in a time dependent manner. Whole cell extracts
were prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to differentiate in the
presence of NP (1 nM) at different times post MDI. Cells were treated every 24 h with a fresh
bolus of NP after their initial treatment. One hundred fifty μg of each sample was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Each figure
represents an experiment independently performed three times.
preadipocytes were pretreated with NP (+) for the times indicated, and then exposed to an acute
10 min treatment of insulin. Although a 10 min insulin treatment resulted in the activation of
IRS-1 Tyr896, pretreatment with NP for various times prior to insulin stimulation resulted in a
decrease in IRS-1 Tyr896 phosphorylation. The efficacy of NP was demonstrated by observing
the activation of STAT3 Tyr705. ERK (MAPK) protein levels demonstrate even loading.
Since we observed a decrease in insulin signaling with NP pretreatment, we examined the
ability of NP to regulate insulin-stimulated glucose uptake in 3T3-L1 adipocytes. As shown in
Figure 3.13, a 10 min treatment with insulin resulted in a nearly 5-fold increase in glucose uptake
as compared to the vehicle treated cells. However, following a 6 h pretreatment with NP, we
observed a substantial decrease in insulin-stimulated glucose uptake compared with controls. The
lack of insulin stimulated uptake was not due to a significant increase in basal glucose uptake.
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Figure 3.11 Neuropoietin inhibits insulin signaling. Fully differentiated 3T3-L1 adipocytes were
pre-treated with NP (1 nM) for the times indicated. Next, the cells were then treated for 10 min
with insulin (50 nM). Following the treatment, whole cell extracts were prepared, and one
hundred μg of each sample was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. This is a representative experiment independently performed
three times.

Figure 3.12 Neuropoietin inhibits insulin signaling in preadipocytes. Confluent 3T3-L1
preadipocytes were pre-treated with NP (1 nM) for the times indicated. Next, the cells were
treated for 10 min with insulin (50 nM). Following the treatment, whole cell extracts were
prepared, and one hundred twenty μg of each sample was separated by SDS-PAGE, transferred
to nitrocellulose, and subjected to Western blot analysis. This is a representative experiment
independently performed three times.
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Figure 3.13 Neuropoietin inhibits insulin-stimulated glucose uptake. Fully differentiated 3T3-L1
adipocytes were serum deprived for 2 h and then treated with NP (1 nM) for 6 h. After the
pretreatment, cells were stimulated with insulin (50 nM) for 10 min. Glucose uptake was
initiated by addition of 2-[3H] deoxyglucose. The glucose uptake values shown represent the
mean +/- S.E. of triplicate determinations from four independent experiments.
The data in Figures 3.11-3.13 clearly indicated that NP negatively affects insulin
signaling in adipocytes in vitro; therefore, we wanted to determine if NP could attenuate insulin
signaling in adipose tissue in vivo. C57B1/6J mice were injected with either vehicle (saline) or
insulin, with or without a pre-injection of NP. The mice were treated for 15 min with insulin
alone or following either a 30 min or 90 min NP pretreatment.
As shown in Figures 3.14 and 3.15, a 15 min insulin treatment resulted in the activation
of Akt Ser473. Although we did not see a decrease in Akt Ser473 signaling after the 30 min NP
pretreatment, we observed a significant attenuation in Akt activation after 1.5 h with each NP
pretreatment in both the epididymal and retroperitoneal adipose tissues. The efficacy of NP was
assessed by the activation of STAT3 Tyr705, and ERK (MAPK) protein levels were observed to
demonstrate even loading.
61

Figure 3.14 Neuropoietin attenuates insulin signaling in adipose tissue in vivo. Seven-week old
male C57B1/6J mice were given an intraperitoneal injection of either vehicle (saline) control, or
insulin (5U/kg), with or without a pre-injection of NP (0.20 µg/g animal). Two animals were
used for each condition. The mice were treated with insulin alone or following either a 30 min
or 90 min NP pretreatment. After the mice were injected with insulin for 15 min, they were
sacrificed, and epididymal fat pads were immediately removed and frozen in liquid nitrogen.
Two hundred fifty μg of each tissue extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. This is a representative experiment
independently performed twice on separate groups of mice.

Figure 3.15 Neuropoietin attenuates insulin signaling in adipose tissue in vivo. Seven-week old
male C57B1/6J mice were given an intraperitoneal injection of either vehicle (saline) control, or
insulin (5U/kg), with or without a pre-injection of NP (0.20 mg/g animal). Two animals were
used for each condition. The mice were treated with insulin alone or following either a 30 min
or 90 min NP pretreatment. After the mice were injected with insulin for 15 min, they were
sacrificed, and retroperitoneal fat pads were immediately removed and frozen in liquid nitrogen.
One hundred fifty μg (retroperitoneal) of each tissue extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis. This is a representative
experiment independently performed twice on separate groups of mice.
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3.4 Discussion
Due to recent studies that implicate gp130 cytokines, specifically CNTF, as potential
therapeutic targets for obesity, we investigated the actions of NP in adipocytes both in vitro and
in vivo. Even though sequence analysis suggests that the np gene has evolved into a pseudogene
in humans (156), we hypothesized that NP, due to similar functional roles with CNTF, could
induce anti-obesogenic effects and be considered a potential therapeutic treatment. Although NP
signals via the same tripartite receptor complex as CNTF, our findings demonstrate both similar
and opposing roles for NP as compared to CNTF. In adipocytes, both NP and CNTF activate
STAT3 Tyr705 in vivo and in vitro and induce the nuclear translocation of STAT3 but not STATs
1 and 5A in vitro. Our studies also indicate that NP treatment, like CNTF, resulted in ERKs 1
and 2 activation in vivo (209). As shown in Figure 3.4, NP and CNTF (166) are also alike in
their ability to induce SOCS-3 mRNA in 3T3-L1 adipocytes. SOCS-3 proteins have been shown
to play a role in both leptin resistance (226) and insulin resistance (227). Interestingly, SOCS-3
is induced by all known gp130 cytokines (166;222;226;228-231), as well as additional
hormones, including insulin (232), GH (233), and leptin (226). However, many inducers of
SOCS-3, including CTNF, do not induce insulin resistance. It is striking that so many cytokines,
in addition to NP and CNTF result in the activation of STAT3, ERKs 1 and 2 and SOCS-3, yet
the action of these cytokines have different responses despite the activation of the same signaling
proteins.
Although our observations indicated that NP induced the same signaling proteins as
CNTF in adipocytes, we observed different effects of NP, as compared to CNTF, on both
adipogenesis and insulin action. Our results demonstrated that NP can inhibit adipogenesis in a
dose and time dependent manner in 3T3-L1 cells, whereas CNTF does not attenuate
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adipogenesis in this model system (165). The different effects do not appear to be due to altered
levels of STAT3 activation as equivalent levels of NP and CNTF results in similar activation of
STAT3 (data not shown). CT-1, LIF, and OSM activate STAT3 in a manner equivalent to NP
(Figure 3.1), but only OSM and NP inhibit differentiation (Figure 3.8). In addition, the ability of
NP to block adipogenesis does not seem to be dependent on the presence of insulin or the
negative effects on insulin action.

Although NP can attenuate insulin signaling in both

preadipocytes (Figure 3.12) and adipocytes (Figure 3.11), our data indicate that NP could inhibit
adipocyte differentiation in the absence of insulin (Figure 3.7). Of all the gp130 cytokines, NP is
the most structurally and functionally related to CNTF and CT-1, yet neither CNTF nor CT-1
attenuate adipogenesis (165;166). These observations suggest the specificity of these gp130
cytokines to modulate adipocyte differentiation involves more than their ability to activate
STAT3 and ERK and induce SOCS-3 expression and indicate that NP possesses unique
signaling abilities that differ from CNTF despite use of the same receptor complex.
Despite the presence of CNTFRα in skeletal muscle (160), our results demonstrate that
acute NP treatment failed to activate STAT3 Tyr705 in skeletal muscle in vivo, in contrast to
CNTF which induced STAT3 Tyr705 phosphorylation in the skeletal muscle of rodents (165). In
addition, CNTF has been shown to increase fat oxidation and reduce insulin resistance via an
AMP-activated protein kinase (AMPK)-dependent mechanism in skeletal muscle (214). It is
possible that NP could also mediate signal transduction in skeletal muscle via other signaling
pathways that are independent of the JAK/STAT pathway, as we did not test this hypothesis in
our experiments.
Importantly, our studies indicate that NP treatment not only attenuates insulin signaling
in vitro, as demonstrated by decreased activation of both IRS-1 Tyr896 and Akt Ser473, but also in
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vivo, as evidenced by the reduction in Akt activation. In comparison, CNTF treatment was
shown to act synergistically with insulin to increase the activation of both IRS-1 Tyr896 and Akt
Ser473 in cultured adipocytes (165) and in vivo studies demonstrated that CNTF could improve
insulin sensitivity in diet-induced and genetic models of obesity (214). In addition to our
findings that NP negatively regulates insulin signaling proteins, we demonstrated that NP
treatment impaired insulin-stimulated glucose uptake in cultured adipocytes. Because CNTF
treatment of cultured adipocytes did not result in insulin resistance (165), these results clearly
indicate significant and opposing roles between NP and CNTF.
This represents the first study to examine the role of NP in adipocytes. Interestingly, we
observed distinct responses between NP and CNTF in adipocytes and skeletal muscle despite
studies which showed that both of these cytokines act through the same signaling receptor
complex (156;160). In summary, our findings indicate that NP can affect adipogenesis and
insulin sensitivity in fat cells both in vitro and in vivo. Based on our present data, NP, unlike
CNTF, is not a suitable anti-obesity therapeutic since it inhibits insulin action and negatively
affects glucose uptake in adipocytes.
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CHAPTER 4
GP130 CYTOKINES HAVE DIFFERENTIAL PATTERNS OF CROSSTALK
SIGNALING BOTH IN VITRO AND IN VIVO
4.1 Introduction
The Interleukin (IL)-6 family of cytokines is a group of functionally and structurally
related proteins that consists of Interleukin-6 (IL-6), Interleukin-11 (IL-11), Interleukin-27 (IL27), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF),
cardiotrophin-1 (CT-1), novel neurotrophin-1/B cell stimulating factor-3 or cardiotrophin-like
cytokine (CLC), and neuropoietin (NP) (reviewed in (234)). Though originally identified as
having distinct properties, these cytokines often have pleiotropic and redundant biological effects
(reviewed in (235)). The IL-6 cytokine family regulates a variety of complex cellular processes,
such

as

hematopoiesis,

immune

response, inflammation, differentiation, mammalian

reproduction, cardiovascular action, and neuronal survival (reviewed in (157)). Their signal
transduction involves the activation of the JAK/STAT pathway, typically activating STAT3 and,
to a lesser extent, STAT1. In addition, the MAPK (ERK) pathway can be activated.
Because all members of this family utilize glycoprotein 130 as a common signal
transducer within their receptor complex for signaling, the IL-6 family is commonly referred to
as the gp130 cytokines (reviewed in (235)). The shared usage of signal transducers in the
receptor complexes may account for the functional redundancy of gp130 cytokines. In addition,
gp130 is ubiquitously expressed in every cell type, which allows for the pleiotropic nature of
these cytokines in a variety of cells.

Although gp130 cytokines are highly redundant in

mediating biological functions, the differences in their activity reside in the additional receptor
components utilized by each member. These cytokines are differentially regulated in multiple
tissues, due to the tissue-specific expression of other receptor components that are required for
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their activation, including the LIF receptor (LIFR) and the cytokine’s specific α receptor.
Likewise, the responsiveness of a given cell type to these cytokines is tightly regulated by the
presence of the cytokine-specific receptor complex, and specific characteristics emerge for each
cytokine.

IL-6 and IL-11 first bind to the IL-6 receptor α and IL-11 receptor α (158),

respectively, and then the complex associates to a gp130 homodimer complex for signaling. IL27 engages a gp130/WSX-1 heterodimeric receptor complex (155). LIF and OSM require the
gp130/LIF receptor (LIFR) complex to mediate signal transduction; OSM can alternatively
utilize a gp130/OSM receptor (OSMR) complex. CT-1 recruits an alpha receptor (159), which to
date has not been characterized, and also signals via gp130/LIFR. CNTF, CLC, and NP all
recruit CNTFRα and then induce the formation of a gp130/LIFR heterodimer for signal
transduction (156;160;161).
In recent years, studies have shown that several gp130 cytokines activate both the
JAK/STAT and MAPK (ERKs 1 and 2) signaling pathways in adipocytes (154;163-167).
Findings from our laboratory indicate that several gp130 cytokines have differential effects on
adipogenesis (166-168), as well as insulin-stimulated glucose uptake (165-168). However, their
functions, as well as their complex signaling cascades, in adipose tissue have been only partially
elucidated. Previous studies from our lab indicate that gp130 cytokines have the unique ability
to crosstalk with other members of the gp130 family to alter one another’s signaling (169), and
this inhibition of signaling correlates with the degradation of the LIFR and its loss at the plasma
membrane. In this follow-up study, our novel data demonstrate that NP, a gp130 cytokine
characterized as signaling via the LIFR, does not have the capability to crosstalk with other
gp130 family members. Several gp130 cytokines have the ability to block NP signaling, but NP
does not inhibit the signaling of other gp130 family members because it does not result in LIFR
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phosphorylation and degradation. We also demonstrated that mOSM crosstalks in a distinct
manner from hOSM, which can be attributed to LIFR activation. Collectively, our data show
that gp130 cytokines exert differential crosstalk signaling capabilities in both cultured adipocytes
in vitro and adipose tissue in vivo, and the inhibitory crosstalk is not dependent on new protein
synthesis or the activation of MAPK.
4.2 Materials and Methods
Materials – Dulbecco’s Modified Eagle’s Media (DMEM) was purchased from Sigma. Bovine
and fetal bovine (FBS) sera were purchased from Atlanta Biological. Mouse recombinant NP,
mouse recombinant CT-1, mouse recombinant OSM, mouse recombinant OSMRβ antibody were
all purchased from R&D Systems. Recombinant human OSM was purchased from Invitrogen,
and mouse recombinant LIF was purchased from BD Transduction.

Cycloheximide was

purchased from Sigma, and 4G10 was purchased from Upstate. Both STAT3 and phosphospecific STAT3 (Y705) monoclonal antibodies were purchased from BD Transduction. Both the
MAPK (ERK) and LIFR polyclonal antibodies and the PPARγ monoclonal antibody were all
purchased from Santa Cruz. The polyclonal anti-active MAPK (ERK1/2) antibody and U0126
inhibitor were purchased from Promega. Protein-A agarose was purchased from Repligen
Corporation. Nitrocellulose was purchased from Bio-Rad. The BCA kit and the enhanced
chemiluminescence kit were purchased form Pierce. Horseradish peroxidase (HRP)-conjugated
secondary antibodies were purchased from Jackson ImmunoResearch Laboratories.
Cell Culture – Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence
in DMEM containing 10% bovine serum. Medium was changed every 48 h. Cells were induced
to differentiate by changing the medium to DMEM containing 10% fetal bovine serum (FBS),
0.5 mM 3-isobutylmethylxanthine, 1 μM dexamethasone, and 1.7 μM insulin (MDI). After 48 h,
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this medium was replaced with DMEM supplemented with 10% FBS and cells were maintained
in this medium until utilized for experimentation.
Preparation of Whole Cell Extracts – Cell monolayers of 3T3-L1 adipocytes were harvested in
a non-denaturing buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM
EDTA, 1% Triton-X 100, 0.5% Igepal CA-630, 1 μM phenylmethylsulfonyl fluoride (PMSF), 1
μM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium
vanadate, and then frozen. Next, the samples were thawed and centrifuged at 10,000 x g at 4oC
for 10 minutes. Supernatants containing whole cell extracts were analyzed for protein content
using a BCA kit according to the manufacturer’s instructions.
Rodent Adipose Tissue Isolation – Animals were euthanized by cervical dislocation, and
tissues were immediately removed and frozen in liquid nitrogen. Frozen tissues were
homogenized in a buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM
EDTA, 1% Triton-X 100, 0.5% Igepal CA-630, 1 μM PMSF, 1 μM pepstatin, and 50 trypsin
inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium vanadate. Homogenates
were centrifuged for 10 minutes at 1,000 x g to remove any debris and insoluble material and
then analyzed for protein content. All animal studies were carried out with protocols which were
reviewed and approved by institutional animal care and use committees.
Immunoprecipitations (IPs) of LIFR or OSMRβ from Adipocyte Extracts – Cell monolayers
of 3T3-L1 adipocytes were harvested under non-denaturing conditions following treatment with
respective cytokines, and the protein content of the whole-cell extracts was analyzed as described
above.

The protein extracts were preincubated with protein-A agarose, and the resulting

supernatants were then incubated with 5 µg of either the LIFR antibody or the OSMRβ antibody
for 2 hours at 4oC. Protein-A agarose was added to the mixture, and the samples were rotated for
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an additional hour. Bound LIFR or OSMRβ and any associated proteins were isolated by
pelleting this mixture. The pellets were rinsed twice with phosphate-buffered saline (PBS), and
the bound proteins were eluted from the agarose by incubation at 100oC for 10 minutes after the
addition of Laemmli sample buffer. These samples were separated by sodium dodecyl sulfate
(SDS)- polyacrylamide gel electrophoresis and analyzed by Western blotting with 4G10
antibody.
Gel Electrophoresis and Western Blot Analysis – Proteins were separated in 7.5%
polyacrylamide (acrylamide from National Diagnostics) gels containing sodium dodecyl sulfate
(SDS) according to Laemmli (187) and transferred to nitrocellulose membrane in 25 mM Tris,
192 mM glycine, and 20% methanol. Following transfer, the membrane was blocked overnight
in 4% milk at 4oC. Results were visualized with horseradish peroxidase (HRP)-conjugated
secondary antibodies and enhanced chemiluminescence.
4.3 Results
Previous studies from our laboratory demonstrated that gp130 cytokines have the ability
to crosstalk with other members in the gp130 family, which results in altering of subsequent
signaling (169). In recent studies, we have shown that a newly discovered gp130 cytokine,
Neuropoietin (NP), can activate STAT3 tyrosine phosphorylation in adipocytes both in vitro and
in vivo (167). Therefore, we wanted to examine the ability of NP to modulate the signaling of
other gp130 cytokines. In addition, previous crosstalk studies were performed using human
oncostatin M (hOSM). Evidence shows that murine OSM (mOSM) signals differently than
hOSM in murine cells and utilizes the OSM receptor β (OSMRβ), as opposed to the leukemia
inhibitory factor receptor (LIFR), in the receptor complex (236). Hence, we wanted to confirm
these observations in 3T3-L1 cells and examine the ability of mOSM to crosstalk with other
70

gp130 family members. We pretreated fully differentiated 3T3-L1 adipocytes with several
different gp130 cytokines (CT-1, LIF, and NP) for 6-hr, followed by an acute 10 min treatment
with CT-1, LIF, mOSM, or NP. To ensure the efficacy of each cytokine, the activation of
STAT3 Tyr705 was observed with no pretreatment.

As shown in Figures 4.1-4.2, a 6-hr

pretreatment with CT-1 or LIF completely blocked the STAT3 activation induced by a 10 min
treatment of CT-1, LIF, or NP, but did not attenuate mOSM. In addition, we observed the same
pattern of inhibition in the activation of MAPK (ERKs 1 and 2). Our data from Figure 4.3
demonstrate that STAT3 activation by CT-1, LIF, and mOSM was not attenuated by a 6-hr NP
pretreatment. Therefore, several gp130 cytokines have the ability to block NP signaling, but NP
does not inhibit the signaling of other gp130 family members. ERK (MAPK) protein levels are
shown to demonstrate even loading in each experiment.

Figure 4.1 CT-1 pretreatment inhibits CT-1, LIF, and NP signaling, but not mOSM, in 3T3-L1
adipocytes. Fully differentiated 3T3-L1 adipocytes received no pretreatment or were
preincubated with 1 nM CT-1 for 6 hr. Next, the cells were treated for 10 min with 1 nM CT-1,
1 nM LIF, 1 nM mOSM, or 1 nM NP. After the acute treatment, whole cell extracts were
prepared, and 150 µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. This is a representative experiment performed
independently four times.

71

Figure 4.2 LIF pretreatment inhibits CT-1, LIF, and NP signaling, but not mOSM, in 3T3-L1
adipocytes. Fully differentiated 3T3-L1 adipocytes received no pretreatment or were
preincubated with 1 nM LIF for 6 hr. Next, the cells were treated for 10 min with 1 nM CT-1, 1
nM LIF, 1 nM mOSM, or 1 nM NP. After the treatment, whole cell extracts were prepared, and
150 µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis. This is a representative experiment performed independently four
times.

Figure 4.3 NP pretreatment does not inhibit signaling of other gp130 cytokines. Fully
differentiated 3T3-L1 adipocytes received no pretreatment or were preincubated with 1 nM NP
for 6 hr. Next, the cells were treated for 10 min with 1 nM CT-1, 1 nM LIF, 1 nM mOSM, or 1
nM NP. After the treatment, whole cell extracts were prepared, and 150 µg of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis.
This is a representative experiment performed independently four times.
In order to observe the differences in crosstalk signaling between mOSM and hOSM and
other gp130 cytokines, we pretreated with CT-1 or LIF for 6 hr, followed by a 10 min treatment
with either mOSM or hOSM. The activation of STAT3 Tyr705 by acute 10 min treatments of
each cytokine, with no pretreatment, was observed to show efficacy of signaling. Our results
show that neither a CT-1 nor a LIF pretreatment inhibited mOSM STAT3 activation; however,
72

both CT-1 and LIF attenuated hOSM signaling, as evidenced by the decrease in STAT3 Tyr705.
ERK (MAPK) protein levels are shown to demonstrate even loading.

Figure 4.4 CT-1 and LIF attenuate hOSM signaling, but not mOSM signaling.
Fully
differentiated 3T3-L1 adipocytes were pretreated with 1 nM CT or 1 nM LIF for 6-hr. Next, the
cells were treated for 10 min with 1 nM mOSM, or 1 nM hOSM. After the treatment, whole cell
extracts were prepared, and 160 µg of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. This is a representative experiment
performed independently two times.
Data from Figures 4.1- 4.4, as well as other studies (169), demonstrate that the gp130
cytokines CT-1, LIF, and hOSM crosstalk to inhibit one another’s signaling; however, both NP
and mOSM have distinct crosstalk capabilities. In order to further examine the crosstalk ability
of mOSM, hOSM, and NP, we pretreated 3T3-L1 adipocytes with these cytokines for 6-hr.
Next, we treated the cells with NP, mOSM, or hOSM for 10 min. Our data in Figure 4.5 show
that hOSM, but not mOSM, inhibited NP signaling, as evidenced by the decreased activation of
STAT3 Tyr705 and MAPK. Conversely, NP did not attenuate either mOSM or hOSM; only NP
signaling was blocked. ERK (MAPK) protein levels are shown to demonstrate even loading.
The mechanisms underlying the crosstalk of the IL-6 family of cytokines have not been fully
elucidated. Therefore, we wanted to further investigate plausible factors that may be involved
and impact the interaction between gp130 cytokines.
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Figure 4.5 mOSM and NP crosstalk differently than other gp130 cytokines. Fully differentiated
3T3-L1 adipocytes were pretreated with 1 nM mOSM, 1 nM hOSM, or 1nM NP for 6-hr. Next,
the cells were treated for 10 min with 1 nM mOSM, 1 nM hOSM, or 1nM NP. After the
treatment, whole cell extracts were prepared, and 160 µg of each extract was separated by SDSPAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a
representative experiment performed independently two times.
Various lines of evidence show that gp130 cytokines induce suppressors of cytokine
signaling (SOCS) proteins (166-168;222). These proteins negatively regulate cytokine signal
transduction, and expression is dependent on new protein synthesis. Therefore, to determine if
the inhibitory crosstalk exerted by gp130 cytokines could be a result of newly synthesized SOCS
proteins, we pretreated fully differentiated 3T3-L1 adipocytes for 4-hr with CT-1, LIF, or NP in
the presence or absence of cycloheximide, an inhibitor of new protein synthesis. Next, we
treated the cells with an acute 10 min treatment of CT-1. Adipocytes with no pretreatment were
observed to show the efficacy of CT-1 signaling. As indicated in Figure 4.6, the same pattern of
crosstalk was observed in the presence or absence of cycloheximide. Both CT-1 and LIF blocked
the signaling of an acute CT-1 treatment, as evidenced by a drastic decrease in STAT3 Tyr705
and MAPK activation. In addition, NP pretreatment did not inhibit CT-1 signaling. Both STAT3
and ERK (MAPK) protein levels are shown to demonstrate even loading. The expression of
PPARγ, a labile transcription factor, is included to show efficacy of the cycloheximide.
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Figure 4.6 Crosstalk of gp130 cytokines is not dependent on new protein synthesis. Fully
differentiated 3T3-L1 adipocytes were pretreated with 1 nM CT-1, 1 nM LIF, or 1nM NP for 4hr in the presence or absence of a 30 min 5 μM cycloheximide preincubation. The cells were
then treated (+) for 10 min with 1 nM CT-1. After the treatment, whole cell extracts were
prepared, and 150 µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. This is a representative experiment performed
independently four times.
In addition to the JAK/STAT pathway, gp130 cytokines can also activate the MAPK
(mitogen-activated protein kinase) cascade (reviewed in (157)). In order to determine whether
the crosstalk of gp130 family members is dependent on the activation of ERKS 1 and 2, we
pretreated fully differentiated 3T3-L1 adipocytes with CT-1, NP, or LIF for 3-hr in the presence
or absence of U0126, a selective ERK 1 and 2 inhibitor. Cells were then given an acute 15 min
treatment (+) of LIF or NP. The efficacy of both LIF and NP signaling was observed in
adipocytes with no pretreatment. As demonstrated in Figures 4.7-4.10, the absence of MAPK
activation had no effect on the crosstalk signaling of gp130 cytokines. Figures 4.7 and 4.8
indicate that both CT-1 and LIF pretreatments blocked an acute treatment of LIF, as evidenced
by the decrease in both STAT3 Tyr705 and MAPK activation.
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Figure 4.7 Crosstalk of gp130 cytokines is not dependent on the activation of MAPK. Fully
differentiated 3T3-L1 adipocytes were pretreated with 1 nM CT-1 or 1nM NP for 3-hr in the
presence or absence of a 30 min 5 μM U0126 preincubation. The cells were then treated (+) for
10 min with 1 nM LIF. After the treatment, whole cell extracts were prepared, and 150 µg of
each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. This is a representative experiment performed independently three times.

Figure 4.8 Crosstalk of gp130 cytokines is not dependent on the activation of MAPK. Fully
differentiated 3T3-L1 adipocytes were pretreated with 1 nM LIF for 3-hr in the presence or
absence of a 30 min 5 μM U0126 preincubation. The cells were then treated (+) for 10 min with
1 nM LIF. After the treatment, whole cell extracts were prepared, and 150 µg of each extract
was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis. This is a representative experiment performed independently three times.
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Likewise, NP pretreatment had no effect on LIF’s activation of STAT3 or MAPK. In addition,
NP signaling was greatly attenuated by pretreatments with CT-1, LIF, and NP, which
corresponds with our previous experiments (Figures 4.9 and 4.10). In each experiment, STAT3
and MAPK protein levels are shown to demonstrate even loading, and the efficacy of the U0126
inhibitor was validated by the decrease in active MAPK following a 30 min preincubation.

Figures 4.9 Crosstalk of gp130 cytokines is not dependent on the activation of MAPK. Fully
differentiated 3T3-L1 adipocytes were pretreated with 1 nM CT-1 or 1nM NP for 3-hr in the
presence or absence of a 30 min 5 μM U0126 preincubation. The cells were then treated (+) for
10 min with 1 nM NP. After the treatment, whole cell extracts were prepared, and 150 µg of
each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. This is a representative experiment performed independently three times.
The data from Figures 4.1-4.10 evaluate gp130 cytokine signaling in 3T3-L1 adipocytes
in vitro; hence, we wanted to further examine the interactions among these cytokines in vivo. To
conduct these studies, Sprague Dawley rats were injected with either vehicle (saline), CT-1
(0.1μg/g animal), or LIF (0.1 μg/g animal), with or without an 8-hr pre-injection of LIF. The
animals were sacrificed 15 minutes following the second injection. As shown in Figure 4.11 and
4.12, both a CT-1 and a LIF injection induced the activation of STAT3 Tyr705 and MAPK in both
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Figures 4.10 Crosstalk of gp130 cytokines is not dependent on the activation of MAPK. Fully
differentiated 3T3-L1 adipocytes were pretreated with 1 nM CT-1, 1 nM LIF, or 1nM NP for 3hr in the presence or absence of a 30 min 5 μM U0126 preincubation. The cells were then
treated (+) for 10 min with 1 nM LIF or 1 nM NP. After the treatment, whole cell extracts were
prepared, and 150 µg of each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. This is a representative experiment performed
independently three times.
the epididymal and retroperitoneal adipose tissues. However, a preinjection with LIF inhibited
the STAT3 tyrosine phosphorylation of both CT-1 and LIF in white adipose tissue.

The

activation of MAPK was also greatly attenuated in each tissue. STAT3 and MAPK protein levels
are shown to demonstrate even loading.
In addition to observing the interaction of CT-1 and LIF in vivo, we examined the
crosstalk signaling of NP and mOSM in adipose tissue in vivo. Previous studies from our lab
showed that NP can induce STAT3 tyrosine phosphorylation in vivo (167); however, NP
interaction with other gp130 cytokines has not been previously observed. Sprague Dawley rats
were injected with either vehicle (saline), NP (0.1μg/g animal), or mOSM (0.1μg/g animal), with
or without a 5 hr pre-injection of NP. The animals were sacrificed 20 minutes following the
second injection. As shown in Figure 4.13, both a NP and a mOSM injection induced the
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Figure 4.11

Figure 4.12
Figures 4.11 and 4.12 LIF treatment in vivo blocks subsequent CT-1 and LIF signaling in rodent
fat pads. Six week old male Sprague Dawley rats were given an intraperitoneal injection of
vehicle (saline) control, CT-1 (0.1 μg/g animal), or LIF (0.1 μg/g animal), with or without an 8
hr preinjection of LIF. Fifteen minutes after the second injection the rats were sacrificed and
both retroperitoneal and epididymal fat pads were immediately removed and frozen in liquid
nitrogen. 220 μg of retroperitoneal and 350 μg of epididymal tissue extract were separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. The data in
each figure is generated from the same exposure of the same blot. Each figure is a representative
experiment independently performed three times.
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activation of STAT3 Tyr705 in retroperitoneal adipose tissue. Our data indicate that a NP
pretreatment did not inhibit the mOSM induction of STAT3 tyrosine phosphorylation; but, the
NP induced STAT3 Tyr705 was abolished. These findings correlate with previous in vitro data
(Figure 4.5). MAPK protein levels are shown to demonstrate even loading.

Figures 4.13 NP pretreatment inhibits NP signaling, but not mOSM in adipose tissue in vivo.
Six week old male Sprague Dawley rats were given an intraperitoneal injection of vehicle
(saline) control, NP (0.1μg/g animal), or mOSM (0.1μg/g animal), with or without a 5 hr
preinjection of NP. Twenty minutes after the second injection the rats were sacrificed and the
retroperitoneal fat pad was immediately removed and frozen in liquid nitrogen. 150 μg of
retroperitoneal tissue extract was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. This is a representative experiment independently performed
three times.
Our in vivo studies demonstrate gp130 cytokine signaling in only epididymal and
retroperitoneal fat pads. In order to gauge our studies in white adipose tissue, we analyzed
brown adipose tissue (BAT), skeletal muscle, and liver extracts to test their sensitivity to gp130
cytokines. Tissue samples were extracted from Sprague Dawley rats following an injection with
either vehicle (saline), CT-1 (.1μg/g animal), LIF (.1μg/g animal), NP (.1μg/g animal), or mOSM
(.1μg/g animal). Figures 4.14 and 4.15 show that CT-1, LIF, NP, and mOSM induced STAT3
tyrosine phosphorylation, as well as MAPK activation, in only retroperitoneal and epididymal
adipose tissue, but not in BAT, skeletal muscle, or liver. Hence, our data indicate that gp130
cytokine action is highly enriched in adipose tissue.

MAPK protein levels are shown to

demonstrate even loading, relative to the amount of protein added for each tissue.
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Figure 4.14

Figure 4.15
Figures 4.14 and 4.15 CT-1, LIF, NP, and mOSM induce STAT3 tyrosine phosphorylation in
only retroperitoneal and epididymal adipose tissue extracts. Six week old male Sprague Dawley
rats were given an intraperitoneal injection of vehicle (saline) control, CT-1 (0.1μg/g animal),
LIF (0.1μg/g animal), NP (0.1μg/g animal), or mOSM (0.1μg/g animal). Fifteen minutes after
the injection the rats were sacrificed and the epididymal, retroperitoneal, brown adipose tissue
(BAT), skeletal muscle, and liver extracts were immediately removed and frozen in liquid
nitrogen. 220 μg of epididymal, retroperitoneal, and BAT extracts and 440 μg of skeletal muscle
and liver extracts were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. This is a representative experiment independently performed three times.
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Because we observed specificity of gp130 family signaling in adipose tissue, we wanted
to ensure that our findings were not due to the lack of essential receptor complex components in
each tissue. It is well known that many gp130 cytokines utilize the leukemia inhibitory factor
receptor (LIFR) as an important signal transducer in the receptor complex (reviewed in Heinrich
(157)). Therefore, we examined the expression of the LIFR in retroperitoneal, epididymal, BAT,
skeletal muscle, and liver extracts that were utilized for our in vivo studies. As shown in Figure
4.16, a substantial amount of the LIFR was present in each tissue. Ironically, LIFR was more
highly expressed in other tissues, as compared to adipose tissue (retroperitoneal), yet these
tissues were not responsive to the gp130 cytokines.

Figure 4.16 The LIFR is expressed in brown adipose tissue (BAT), skeletal muscle, and liver, as
well as adipose tissue. Extracts were taken from six week old Sprague Dawley rats that were
given only a vehicle (saline) injection. The rats were sacrificed, and the epididymal,
retroperitoneal, brown adipose tissue (BAT), skeletal muscle, and liver extracts were
immediately removed and frozen in liquid nitrogen. 200 μg of each tissue extract was separated
by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a
representative experiment independently performed two times.
Previous studies by Zvonic et al. postulated that the inhibitory crosstalk among certain
gp130 cytokines in adipocytes occurs as a result of specific degradation of the LIFR via a
lysosome-mediated pathway (169). These studies also demonstrated that LIF, CT-1, and hOSM
had profound effects on LIFR degradation; hence, subsequent signaling by certain gp130
cytokines was attenuated due to the lack of the LIFR. In the studies shown above, we observed
that NP pretreatment does not inhibit signaling of other gp130 family members; therefore, NP
crosstalks differently than other gp130 cytokines. Hence, we wanted to determine if NP resulted
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in decreased LIFR levels in 3T3-L1 adipocytes.

We treated fully differentiated 3T3-L1

adipocytes with cylcoheximide (CH), in the presence or absence of LIF or NP. As shown in
Figure 4.17, the expression levels of LIFR in adipocytes treated with LIF dramatically decreased
within 1 hr; however, NP treatment did not cause a substantial decrease in LIFR expression. The
efficacy of both LIF and NP was shown by the activation of STAT3 Tyr705. We also observed
that NP failed to cause a decrease in LIFR expression in OP9 mouse stromal cells, a newly
characterized adipocyte cell culture model (237) (data not shown).

Figure 4.17 NP does not induce the degradation of the LIFR. Fully differentiated 3T3-L1
adipocytes were treated with either 1 nM LIF or 1 nM NP in the presence of 5 μM
cycloheximide (CH). Whole cell extracts were prepared from adipocytes that were untreated (0)
or treated at the times indicated. 125 μg of extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. This is a representative experiment
independently performed three times.
Gp130 cytokines are known to induce the tyrosine phosphorylation of their recruited
signal transducer receptors, including the LIFR, upon ligand binding. Because data in Figure
4.17 indicate that NP does not induce LIFR degradation, we examined the ability of NP to induce
the tyrosine phosphorylation of the LIFR, since other studies have reported that NP signals via
the LIFR (156). The ability of gp130 cytokines to phosphorylate the LIFR was examined by
immunoprecipitating LIFR from whole cell extracts isolated from cells treated with LIF, mOSM,
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hOSM, or NP. Phosphorylation of the LIFR was observed by western blotting with 4G10, an
anti-phosphotyrosine antibody. As shown in Figure 4.18, both LIF and hOSM, but not NP,
induced the phosphorylation of the LIFR, and this effect was not attributed to differences in
LIFR expression. The lack of LIFR phosphorylation by mOSM treated cells supports previous
studies that revealed an alternative receptor complex in murine cells for this cytokine.
Collectively, our data demonstrate that NP does not cause the degradation or tyrosine
phosphorylation of the LIFR as we have observed for other gp130 cytokines. The efficacy of
each cytokine was shown by the substantial activation of STAT3 Tyr705.

Figure 4.18 NP does not cause the tyrosine phosphorylation of the LIFR. Whole cell extracts
were isolated from fully differentated 3T3-L1 adipocytes that were harvested after no treatment
(CTL) or an acute 6 minute treatment with 1 nM LIF, 1 nM mOSM, 1 nM hOSM, or 1nM NP.
Each extract was subjected to immunoprecipitation (IP) with an antibody directed against the
LIFR and Western blotting analysis with 4G10, an anti-phosphotyrosine antibody. 700 μg of
protein was used for IP, and 90 μg of protein was used for Western blotting. One IP contained
buffer, but not extract, and is labeled as Mock. This is a representative experiment
independently performed four times.
Because our findings indicated that NP does not induce phosphorylation of the LIFR, we
wanted to determine if NP would cause the tyrosine phosphorylation of another gp130 cytokine
signaling receptor component. The oncostatin M receptor β (OSMRβ) is similar in structure to
the LIFR and is utilized by mOSM for signal transduction. The ability of both mOSM and NP to
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tyrosine phosphorylate the OSMRβ was examined by immunoprecipitating cytokine-treated
whole cell extracts with an antibody directed against OSMRβ and analyzing these precipitates
with western blotting to observe the presence of tyrosine phosphorylated proteins, using a 4G10
anti-phosphotyrosine antibody. As shown in Figure 4.19, mOSM, but not NP, induced the
tyrosine phosphorylation of the OSMRβ, and this effect was not attributed to differences in
OSMRβ expression. The efficacy of each cytokine was shown by the substantial activation of
STAT3 Tyr705.

Figure 4.19 NP does not cause the tyrosine phosphorylation of the OSMRβ. Whole cell extracts
were isolated from fully differentated 3T3-L1 adipocytes that were harvested after no treatment
(CTL) or an acute 6 minute treatment with 1 nM mOSM, or 1nM NP. Each extract was
subjected to immunoprecipitation (IP) with an antibody directed against the OSMRβ and
Western blotting analysis with 4G10, an anti-phosphotyrosine antibody. 600 μg of protein was
used for IP, and 90 μg of protein was used for Western blotting. One IP contained buffer, but not
extract, and is labeled as Mock. This is a representative experiment independently performed
three times.
4.4 Concluding Summary
Although the mechanisms underlying the actions of gp130 cytokines have not been fully
elucidated, it is now common knowledge that members of the gp130 family activate STAT
proteins, as well as the MAPK (ERK) pathway in adipocytes.

Previous studies from our

laboratory highlighted the ability of several gp130 cytokines to crosstalk in an inhibitory fashion
with specific gp130 family members in adipocytes as a result of specific degradation of the
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LIFR. Our follow-up studies evaluated the crosstalk signaling of several gp130 cytokines both
in vitro and in vivo. Novel data show that NP does not inhibit the signaling of other gp130
cytokines, presumably because it does not result in LIFR phosphorylation and degradation.
Likewise, mOSM crosstalks in a distinct manner from hOSM, which can be attributed to LIFR
activation. In contrast, many gp130 cytokines, specifically CT-1, LIF, and hOSM, signal in an
antagonistic fashion with one another. We also demonstrate that this crosstalk inhibition is not
dependent on the activation of MAPK or new protein synthesis.
A common feature of many gp130 cytokines is their shared use of not only gp130, but
also LIFR proteins as components of their receptor complex. Some of the most interesting
characteristics of gp130 cytokines involve their pleiotropic and redundant functions, and many
lines of evidence show that these features can be partly attributed to the presence of the signal
transducers in the receptor complex. Our data support the idea that the unique crosstalk ability of
gp130 cytokines could also be due to differential usage of receptor components. Several gp130
family members that utilize the LIFR, including CT-1, LIF, and hOSM, have the ability to
crosstalk with one another in an antagonistic fashion.

Studies show that following gp130

cytokine treatment, LIFR is degraded after internalization (169;238;239), which results in the
loss of LIFR from the plasma membrane and the inability for subsequent signaling. Although
NP was originally characterized as a cytokine that required the LIFR for signal transduction
(156), our novel data indicate that NP does not, in fact, phosphorylate or degrade the LIFR
(Figure 4.17) in the same manner as other gp130 cytokines. Hence, these observations suggest
that NP does not crosstalk and inhibit the signaling of other gp130 cytokines because this
crosstalk is associated with LIFR phosphorylation. Since NP propagates its signal through the
JAK/STAT and MAPK pathways in a manner similar to other gp130 cytokines, our data suggest
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that the lack of signal inhibition may reside at the level of the receptor. We postulate that NP
may utilize an alternative signal transducer in its receptor complex, in addition to gp130 and
CNTFRα. Although we do not know the identity of this NP receptor(s), our data indicate that the
LIFR and OSMRβ (Figure 4.19) are not involved.
We also further examined the mechanistic actions of gp130 cytokines by investigating
potential factors that could impact gp130 crosstalk interaction. Although previous studies in our
laboratory demonstrated that a loss in the induction in SOCS mRNA by gp130 members
coincided with an impairment of signaling by gp130 cytokine pretreatments, we demonstrate that
gp130 inhibitory crosstalk is not dependent on newly synthesized SOCS proteins. Therefore, the
antagonistic signaling of these cytokines is not the result of additional protein function, but most
likely the action of each respective cytokine to bind and induce the degradation of a receptor
component. In addition, though the activation of MAPK (ERKs 1 and 2) by gp130 cytokines
may serve as an essential pathway in other cellular actions, our data show that gp130 crosstalk is
not dependent on MAPK activation (Figures 4.7-4.10).

The mechanisms underlying the

crosstalk of gp130 cytokines are poorly understood; however, we have demonstrated that two
well-established gp130-activated signaling proteins are not the cause of the observed crosstalk.
To our knowledge, no other laboratories have investigated the interactions of various
gp130 cytokines in adipose tissue in vivo. Interestingly, our data indicate that gp130 family
members crosstalk in vivo in the same manner as in vitro, and these effects are likely very
important in adipose tissue since it is highly responsive to cytokine exposure compared to other
insulin sensitive tissues (Figures 4.11-4.15). LIF pretreatment inhibited both LIF and CT-1
subsequent treatments. In addition, NP pretreatment had no effect on an acute treatment of
mOSM. The fact that gp130 cytokines not only activate signaling pathways in vivo, but also
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inhibit subsequent signaling of other gp130 family members confirm that a detailed analysis of
crosstalk mechanisms is relevant for a more detailed perspective of gp130 cytokine function. In
addition, it is well known that in humans there are circulating levels of some gp130 cytokines,
notably IL-6 and CT-1 (reviewed in (162))(240), which greatly contribute to metabolism.
Therefore, it is necessary to understand how these cytokines function and interact, as well as the
inhibitory crosstalk that gp130 cytokines exert on their respective family members. Collectively,
our data provide a basis for future analyses of cytokine interaction; nonetheless, further studies
are needed to examine how these processes could possibly contribute to or affect metabolic
disease states that are characterized by the expression of multiple cytokines, including those
belonging to the gp130 family.
Although few STAT target genes have been identified, numerous lines of evidence
suggest an important role for these transcription factors in adipocytes.

Our studies have

characterized a new STAT5A target gene, PDK4, which plays a critical role in glucose
metabolism. This data provides additional evidence for the importance of STATs in regulating
genes that regulate not only adipocyte function, but also full-body metabolism. Though the
mechanisms underlying the action of STAT3 activators have not been fully elucidated, our novel
studies implicate differential actions of these cytokines in adipocytes. The importance of STAT3
in fat cell metabolism is supported by data indicating that cytokine activators exert unique, yet
significant effects on both adipogenesis and insulin sensitivity. In addition, the metabolic
implications of gp130 cytokine crosstalk remain to be discovered; yet, we speculate that these
interactions may greatly affect the physiological action of these cytokines. Future research will
hopefully lead to insights into the molecular mechanisms regulating whole-body homeostasis
and may contribute to understanding the metabolic defects underlying obesity and T2D.
88

REFERENCES

1. Rosen,ED, Spiegelman,BM: Adipocytes as regulators of energy balance and glucose
homeostasis. Nature 444:847-853, 2006
2. Chan,JM, Rimm,EB, Colditz,GA, Stampfer,MJ, Willett,WC: Obesity, fat distribution,
and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17:961-969,
1994
3. Bastard,JP, Maachi,M, Lagathu,C, Kim,MJ, Caron,M, Vidal,H, Capeau,J, Feve,B: Recent
advances in the relationship between obesity, inflammation, and insulin resistance. Eur
Cytokine Netw 17:4-12, 2006
4.

State-specific prevalence of obesity among adults--United States, 2007. MMWR Morb
Mortal Wkly Rep 57:765-768, 2008

5. Ioannidis,I: The road from obesity to type 2 diabetes. Angiology 59:39S-43S, 2008
6. Smyth,S, Heron,A: Diabetes and obesity: the twin epidemics. Nat Med 12:75-80, 2006
7. Zhang,Y, Proenca,R, Maffei,M, Barone,M, Leopold,L, Friedman,JM: Positional cloning
of the mouse obese gene and its human homologue. Nature 372:425-432, 1994
8. Vazquez-Vela,ME, Torres,N, Tovar,AR: White adipose tissue as endocrine organ and its
role in obesity. Arch Med Res 39:715-728, 2008
9. Scherer,PE, Williams,S, Fogliano,M, Baldini,G, Lodish,HF: A novel serum protein
similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
10. Steppan,CM, Bailey,ST, Bhat,S, Brown,EJ, Banerjee,RR, Wright,CM, Patel,HR,
Ahima,RS, Lazar,MA: The hormone resistin links obesity to diabetes. Nature 409:307312, 2001
11. Savage,DB, Petersen,KF, Shulman,GI: Disordered lipid metabolism and the pathogenesis
of insulin resistance. Physiol Rev 87:507-520, 2007

89

12. Haffner,SM, Stern,MP, Mitchell,BD, Hazuda,HP, Patterson,JK: Incidence of type II
diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity,
and body-fat distribution. Diabetes 39:283-288, 1990
13. Lillioja,S, Mott,DM, Spraul,M, Ferraro,R, Foley,JE, Ravussin,E, Knowler,WC,
Bennett,PH, Bogardus,C: Insulin resistance and insulin secretory dysfunction as
precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima
Indians. N Engl J Med 329:1988-1992, 1993
14. Moitra,J, Mason,MM, Olive,M, Krylov,D, Gavrilova,O, Marcus-Samuels,B,
Feigenbaum,L, Lee,E, Aoyama,T, Eckhaus,M, Reitman,ML, Vinson,C: Life without
white fat: a transgenic mouse. Genes Dev 12:3168-3181, 1998
15. Sovik,O, Vestergaard,H, Trygstad,O, Pedersen,O: Studies of insulin resistance in
congenital generalized lipodystrophy. Acta Paediatr Suppl 413:29-37, 1996
16. Garg,A: Adipose tissue dysfunction in obesity and lipodystrophy. Clin Cornerstone 8
Suppl 4:S7-S13, 2006
17. Sethi,JK, Vidal-Puig,AJ: Thematic review series: adipocyte biology. Adipose tissue
function and plasticity orchestrate nutritional adaptation. J Lipid Res 48:1253-1262, 2007
18. Boden,G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
Diabetes 46:3-10, 1997
19. Goossens,GH: The role of adipose tissue dysfunction in the pathogenesis of obesityrelated insulin resistance. Physiol Behav 94:206-218, 2008
20. Kim,JY, van de,WE, Laplante,M, Azzara,A, Trujillo,ME, Hofmann,SM, Schraw,T,
Durand,JL, Li,H, Li,G, Jelicks,LA, Mehler,MF, Hui,DY, Deshaies,Y, Shulman,GI,
Schwartz,GJ, Scherer,PE: Obesity-associated improvements in metabolic profile through
expansion of adipose tissue. J Clin Invest 117:2621-2637, 2007
21. Miyazaki,Y, Mahankali,A, Matsuda,M, Glass,L, Mahankali,S, Ferrannini,E, Cusi,K,
Mandarino,LJ, DeFronzo,RA: Improved glycemic control and enhanced insulin
sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710719, 2001

90

22. Smith,SR, de,JL, Volaufova,J, Li,Y, Xie,H, Bray,GA: Effect of pioglitazone on body
composition and energy expenditure: a randomized controlled trial. Metabolism 54:2432, 2005
23. Karelis,AD, Brochu,M, Rabasa-Lhoret,R: Can we identify metabolically healthy but
obese individuals (MHO)? Diabetes Metab 30:569-572, 2004
24. Brochu,M, Tchernof,A, Dionne,IJ, Sites,CK, Eltabbakh,GH, Sims,EA, Poehlman,ET:
What are the physical characteristics associated with a normal metabolic profile despite a
high level of obesity in postmenopausal women? J Clin Endocrinol Metab 86:1020-1025,
2001
25. Tan,CY, Vidal-Puig,A: Adipose tissue expandability: the metabolic problems of obesity
may arise from the inability to become more obese. Biochem Soc Trans 36:935-940, 2008
26. Maffeis,C, Silvagni,D, Bonadonna,R, Grezzani,A, Banzato,C, Tato,L: Fat cell size,
insulin sensitivity, and inflammation in obese children. J Pediatr 151:647-652, 2007
27. Paolisso,G, Tataranni,PA, Foley,JE, Bogardus,C, Howard,BV, Ravussin,E: A high
concentration of fasting plasma non-esterified fatty acids is a risk factor for the
development of NIDDM. Diabetologia 38:1213-1217, 1995
28. Weyer,C, Foley,JE, Bogardus,C, Tataranni,PA, Pratley,RE: Enlarged subcutaneous
abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of
insulin resistance. Diabetologia 43:1498-1506, 2000
29. Lofgren,P, Andersson,I, Adolfsson,B, Leijonhufvud,BM, Hertel,K, Hoffstedt,J, Arner,P:
Long-term prospective and controlled studies demonstrate adipose tissue hypercellularity
and relative leptin deficiency in the postobese state. J Clin Endocrinol Metab 90:62076213, 2005
30. Guilherme,A, Virbasius,JV, Puri,V, Czech,MP: Adipocyte dysfunctions linking obesity
to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9:367-377, 2008
31. Sartipy,P, Loskutoff,DJ: Monocyte chemoattractant protein 1 in obesity and insulin
resistance. Proc Natl Acad Sci U S A 100:7265-7270, 2003

91

32. Curat,CA, Miranville,A, Sengenes,C, Diehl,M, Tonus,C, Busse,R, Bouloumie,A: From
blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by
human mature adipocytes. Diabetes 53:1285-1292, 2004
33. Hotamisligil,GS, Arner,P, Caro,JF, Atkinson,RL, Spiegelman,BM: Increased adipose
tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.
J Clin Invest 95:2409-2415, 1995
34. Rotter,V, Nagaev,I, Smith,U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1
adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat
cells from insulin-resistant subjects. J Biol Chem 278:45777-45784, 2003
35. Weisberg,SP, McCann,D, Desai,M, Rosenbaum,M, Leibel,RL, Ferrante,AW, Jr.: Obesity
is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:17961808, 2003
36. Kern,PA, Ranganathan,S, Li,C, Wood,L, Ranganathan,G: Adipose tissue tumor necrosis
factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol
Endocrinol Metab 280:E745-E751, 2001
37. Arita,Y, Kihara,S, Ouchi,N, Takahashi,M, Maeda,K, Miyagawa,J, Hotta,K, Shimomura,I,
Nakamura,T, Miyaoka,K, Kuriyama,H, Nishida,M, Yamashita,S, Okubo,K, Matsubara,K,
Muraguchi,M, Ohmoto,Y, Funahashi,T, Matsuzawa,Y: Paradoxical decrease of an
adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:7983, 1999
38. Hotta,K, Funahashi,T, Arita,Y, Takahashi,M, Matsuda,M, Okamoto,Y, Iwahashi,H,
Kuriyama,H, Ouchi,N, Maeda,K, Nishida,M, Kihara,S, Sakai,N, Nakajima,T,
Hasegawa,K, Muraguchi,M, Ohmoto,Y, Nakamura,T, Yamashita,S, Hanafusa,T,
Matsuzawa,Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in
type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
39. Weyer,C, Funahashi,T, Tanaka,S, Hotta,K, Matsuzawa,Y, Pratley,RE, Tataranni,PA:
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin
resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
40. Considine,RV, Sinha,MK, Heiman,ML, Kriauciunas,A, Stephens,TW, Nyce,MR,
Ohannesian,JP, Marco,CC, McKee,LJ, Bauer,TL, .: Serum immunoreactive-leptin
concentrations in normal-weight and obese humans. N Engl J Med 334:292-295, 1996
92

41. Sopasakis,VR, Sandqvist,M, Gustafson,B, Hammarstedt,A, Schmelz,M, Yang,X,
Jansson,PA, Smith,U: High local concentrations and effects on differentiation implicate
interleukin-6 as a paracrine regulator. Obes Res 12:454-460, 2004
42. Petruschke,T, Hauner,H: Tumor necrosis factor-alpha prevents the differentiation of
human adipocyte precursor cells and causes delipidation of newly developed fat cells. J
Clin Endocrinol Metab 76:742-747, 1993
43. Stephens,JM, Pekala,PH: Transcriptional repression of the C/EBP-alpha and GLUT4
genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and
independent of protein synthesis. J Biol Chem 267:13580-13584, 1992
44. Hauner,H, Petruschke,T, Russ,M, Rohrig,K, Eckel,J: Effects of tumour necrosis factor
alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated
human fat cells in cell culture. Diabetologia 38:764-771, 1995
45. van,HG, Steensberg,A, Sacchetti,M, Fischer,C, Keller,C, Schjerling,P, Hiscock,N,
Moller,K, Saltin,B, Febbraio,MA, Pedersen,BK: Interleukin-6 stimulates lipolysis and fat
oxidation in humans. J Clin Endocrinol Metab 88:3005-3010, 2003
46. Okuno,A, Tamemoto,H, Tobe,K, Ueki,K, Mori,Y, Iwamoto,K, Umesono,K, Akanuma,Y,
Fujiwara,T, Horikoshi,H, Yazaki,Y, Kadowaki,T: Troglitazone increases the number of
small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J
Clin Invest 101:1354-1361, 1998
47. Schernthaner,GH, Kopp,HP, Kriwanek,S, Krzyzanowska,K, Satler,M, Koppensteiner,R,
Schernthaner,G: Effect of massive weight loss induced by bariatric surgery on serum
levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes
Surg 16:709-715, 2006
48. Cancello,R, Henegar,C, Viguerie,N, Taleb,S, Poitou,C, Rouault,C, Coupaye,M,
Pelloux,V, Hugol,D, Bouillot,JL, Bouloumie,A, Barbatelli,G, Cinti,S, Svensson,PA,
Barsh,GS, Zucker,JD, Basdevant,A, Langin,D, Clement,K: Reduction of macrophage
infiltration and chemoattractant gene expression changes in white adipose tissue of
morbidly obese subjects after surgery-induced weight loss. Diabetes 54:2277-2286, 2005
49. Clement,K, Viguerie,N, Poitou,C, Carette,C, Pelloux,V, Curat,CA, Sicard,A, Rome,S,
Benis,A, Zucker,JD, Vidal,H, Laville,M, Barsh,GS, Basdevant,A, Stich,V, Cancello,R,
Langin,D: Weight loss regulates inflammation-related genes in white adipose tissue of
obese subjects. FASEB J 18:1657-1669, 2004
93

50. Green,H, Kehinde,O: An established preadipose cell line and its differentiation in culture.
II. Factors affecting the adipose conversion. Cell 5:19-27, 1975
51. Green,H, Kehinde,O: Spontaneous heritable changes leading to increased adipose
conversion in 3T3 cells. Cell 7:105-113, 1976
52. McKnight,SL, Lane,MD, Gluecksohn-Waelsch,S: Is CCAAT/enhancer-binding protein a
central regulator of energy metabolism? Genes Dev 3:2021-2024, 1989
53. Farmer,SR: Transcriptional control of adipocyte formation. Cell Metab 4:263-273, 2006
54. Chawla,A, Schwarz,EJ, Dimaculangan,DD, Lazar,MA: Peroxisome proliferator-activated
receptor (PPAR) gamma: adipose-predominant expression and induction early in
adipocyte differentiation. Endocrinology 135:798-800, 1994
55. Tontonoz,P, Hu,E, Graves,RA, Budavari,AI, Spiegelman,BM: mPPAR gamma 2: tissuespecific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234, 1994
56. Yokoyama,C, Wang,X, Briggs,MR, Admon,A, Wu,J, Hua,X, Goldstein,JL, Brown,MS:
SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of
the low density lipoprotein receptor gene. Cell 75:187-197, 1993
57. Tontonoz,P, Kim,JB, Graves,RA, Spiegelman,BM: ADD1: a novel helix-loop-helix
transcription factor associated with adipocyte determination and differentiation. Mol Cell
Biol 13:4753-4759, 1993
58. Bernlohr,DA, Angus,CW, Lane,MD, Bolanowski,MA, Kelly,TJ, Jr.: Expression of
specific mRNAs during adipose differentiation: identification of an mRNA encoding a
homologue of myelin P2 protein. Proc Natl Acad Sci U S A 81:5468-5472, 1984
59. Distel,RJ, Ro,HS, Rosen,BS, Groves,DL, Spiegelman,BM: Nucleoprotein complexes that
regulate gene expression in adipocyte differentiation: direct participation of c-fos. Cell
49:835-844, 1987
60. Karin,M, Liu,Z, Zandi,E: AP-1 function and regulation. Curr Opin Cell Biol 9:240-246,
1997

94

61. Song,L, Stephens,JM, Kittur,S, Collins,GD, Nagel,JE, Pekala,PH, Adler,WH: Expression
of c-fos, c-jun and jun B in peripheral blood lymphocytes from young and elderly adults.
Mech Ageing Dev 65:149-156, 1992
62. Endo,H, Sabri,MI, Stephens,JM, Pekala,PH, Kittur,S: Acrylamide induces immediateearly gene expression in rat brain. Brain Res 609:231-236, 1993
63. Mori,T, Sakaue,H, Iguchi,H, Gomi,H, Okada,Y, Takashima,Y, Nakamura,K,
Nakamura,T, Yamauchi,T, Kubota,N, Kadowaki,T, Matsuki,Y, Ogawa,W, Hiramatsu,R,
Kasuga,M: Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of
adipogenesis. J Biol Chem 280:12867-12875, 2005
64. Oishi,Y, Manabe,I, Tobe,K, Tsushima,K, Shindo,T, Fujiu,K, Nishimura,G, Maemura,K,
Yamauchi,T, Kubota,N, Suzuki,R, Kitamura,T, Akira,S, Kadowaki,T, Nagai,R: Kruppellike transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab
1:27-39, 2005
65. Banerjee,SS, Feinberg,MW, Watanabe,M, Gray,S, Haspel,RL, Denkinger,DJ,
Kawahara,R, Hauner,H, Jain,MK: The Kruppel-like factor KLF2 inhibits peroxisome
proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem
278:2581-2584, 2003
66. Gray,S, Feinberg,MW, Hull,S, Kuo,CT, Watanabe,M, Sen-Banerjee,S, DePina,A,
Haspel,R, Jain,MK: The Kruppel-like factor KLF15 regulates the insulin-sensitive
glucose transporter GLUT4. J Biol Chem 277:34322-34328, 2002
67. Birsoy,K, Chen,Z, Friedman,J: Transcriptional regulation of adipogenesis by KLF4. Cell
Metab 7:339-347, 2008
68. Chen,Z, Torrens,JI, Anand,A, Spiegelman,BM, Friedman,JM: Krox20 stimulates
adipogenesis via C/EBPbeta-dependent and -independent mechanisms. Cell Metab 1:93106, 2005
69. Eberle,D, Hegarty,B, Bossard,P, Ferre,P, Foufelle,F: SREBP transcription factors: master
regulators of lipid homeostasis. Biochimie 86:839-848, 2004
70. Shimano,H, Shimomura,I, Hammer,RE, Herz,J, Goldstein,JL, Brown,MS, Horton,JD:
Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a
targeted disruption of the SREBP-1 gene. J Clin Invest 100:2115-2124, 1997
95

71. Yahagi,N, Shimano,H, Hasty,AH, Matsuzaka,T, Ide,T, Yoshikawa,T, Amemiya-Kudo,M,
Tomita,S, Okazaki,H, Tamura,Y, Iizuka,Y, Ohashi,K, Osuga,J, Harada,K, Gotoda,T,
Nagai,R, Ishibashi,S, Yamada,N: Absence of sterol regulatory element-binding protein-1
(SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in
Lep(ob)/Lep(ob) mice. J Biol Chem 277:19353-19357, 2002
72. Kim,JB, Spiegelman,BM: ADD1/SREBP1 promotes adipocyte differentiation and gene
expression linked to fatty acid metabolism. Genes Dev 10:1096-1107, 1996
73. Kim,JB, Wright,HM, Wright,M, Spiegelman,BM: ADD1/SREBP1 activates
PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A
95:4333-4337, 1998
74. Tanaka,T, Yoshida,N, Kishimoto,T, Akira,S: Defective adipocyte differentiation in mice
lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J 16:7432-7443, 1997
75. Wang,ND, Finegold,MJ, Bradley,A, Ou,CN, Abdelsayed,SV, Wilde,MD, Taylor,LR,
Wilson,DR, Darlington,GJ: Impaired energy homeostasis in C/EBP alpha knockout mice.
Science 269:1108-1112, 1995
76. Cao,Z, Umek,RM, McKnight,SL: Regulated expression of three C/EBP isoforms during
adipose conversion of 3T3-L1 cells. Genes Dev 5:1538-1552, 1991
77. Yeh,WC, Cao,Z, Classon,M, McKnight,SL: Cascade regulation of terminal adipocyte
differentiation by three members of the C/EBP family of leucine zipper proteins. Genes
Dev 9:168-181, 1995
78. Wu,Z, Xie,Y, Bucher,NL, Farmer,SR: Conditional ectopic expression of C/EBP beta in
NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev 9:23502363, 1995
79. Wu,Z, Bucher,NL, Farmer,SR: Induction of peroxisome proliferator-activated receptor
gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by
C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 16:4128-4136, 1996
80. Lin,FT, Lane,MD: CCAAT/enhancer binding protein alpha is sufficient to initiate the
3T3-L1 adipocyte differentiation program. Proc Natl Acad Sci U S A 91:8757-8761, 1994

96

81. el Jack,AK, Hamm,JK, Pilch,PF, Farmer,SR: Reconstitution of insulin-sensitive glucose
transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha. J Biol
Chem 274:7946-7951, 1999
82. Wu,Z, Rosen,ED, Brun,R, Hauser,S, Adelmant,G, Troy,AE, McKeon,C, Darlington,GJ,
Spiegelman,BM: Cross-regulation of C/EBP alpha and PPAR gamma controls the
transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 3:151-158, 1999
83. Hamm,JK, Park,BH, Farmer,SR: A role for C/EBPbeta in regulating peroxisome
proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1
preadipocytes. J Biol Chem 276:18464-18471, 2001
84. Rosen,ED, Sarraf,P, Troy,AE, Bradwin,G, Moore,K, Milstone,DS, Spiegelman,BM,
Mortensen,RM: PPAR gamma is required for the differentiation of adipose tissue in vivo
and in vitro. Mol Cell 4:611-617, 1999
85. Barak,Y, Nelson,MC, Ong,ES, Jones,YZ, Ruiz-Lozano,P, Chien,KR, Koder,A,
Evans,RM: PPAR gamma is required for placental, cardiac, and adipose tissue
development. Mol Cell 4:585-595, 1999
86. Tontonoz,P, Hu,E, Spiegelman,BM: Stimulation of adipogenesis in fibroblasts by PPAR
gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
87. Lehmann,JM, Moore,LB, Smith-Oliver,TA, Wilkison,WO, Willson,TM, Kliewer,SA: An
antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
88. He,W, Barak,Y, Hevener,A, Olson,P, Liao,D, Le,J, Nelson,M, Ong,E, Olefsky,JM,
Evans,RM: Adipose-specific peroxisome proliferator-activated receptor gamma knockout
causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A
100:15712-15717, 2003
89. Miles,PD, Barak,Y, He,W, Evans,RM, Olefsky,JM: Improved insulin-sensitivity in mice
heterozygous for PPAR-gamma deficiency. J Clin Invest 105:287-292, 2000
90. Hauser,S, Adelmant,G, Sarraf,P, Wright,HM, Mueller,E, Spiegelman,BM: Degradation
of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent
activation. J Biol Chem 275:18527-18533, 2000
97

91. Floyd,ZE, Stephens,JM: Interferon-gamma-mediated activation and ubiquitinproteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem
277:4062-4068, 2002
92. Floyd,ZE, Stephens,JM: Control of peroxisome proliferator-activated receptor gamma2
stability and activity by SUMOylation. Obes Res 12:921-928, 2004
93. Ohshima,T, Koga,H, Shimotohno,K: Transcriptional activity of peroxisome proliferatoractivated receptor gamma is modulated by SUMO-1 modification. J Biol Chem
279:29551-29557, 2004
94. Yamashita,D, Yamaguchi,T, Shimizu,M, Nakata,N, Hirose,F, Osumi,T: The
transactivating function of peroxisome proliferator-activated receptor gamma is
negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells
9:1017-1029, 2004
95. Pascual,G, Fong,AL, Ogawa,S, Gamliel,A, Li,AC, Perissi,V, Rose,DW, Willson,TM,
Rosenfeld,MG, Glass,CK: A SUMOylation-dependent pathway mediates transrepression
of inflammatory response genes by PPAR-gamma. Nature 437:759-763, 2005
96. Burns,KA, Vanden Heuvel,JP: Modulation of PPAR activity via phosphorylation.
Biochim Biophys Acta 2007
97. Liao,W, Nguyen,MT, Yoshizaki,T, Favelyukis,S, Patsouris,D, Imamura,T, Verma,IM,
Olefsky,JM: Suppression of PPAR{gamma} Attenuates Insulin-Stimulated Glucose
Uptake by Affecting Both GLUT1 and GLUT4 in 3T3-L1 Adipocytes. Am J Physiol
Endocrinol Metab 2007
98. Picard,F, Kurtev,M, Chung,N, Topark-Ngarm,A, Senawong,T, Machado,DO, Leid,M,
McBurney,MW, Guarente,L: Sirt1 promotes fat mobilization in white adipocytes by
repressing PPAR-gamma. Nature 429:771-776, 2004
99. Leff,T, Mathews,ST, Camp,HS: Review: peroxisome proliferator-activated receptorgamma and its role in the development and treatment of diabetes. Exp Diabesity Res
5:99-109, 2004
100. Monajemi,H, Zhang,L, Li,G, Jeninga,EH, Cao,H, Maas,M, Brouwer,CB, Kalkhoven,E,
Stroes,E, Hegele,RA, Leff,T: Familial partial lipodystrophy phenotype resulting from a
98

single-base mutation in deoxyribonucleic acid-binding domain of peroxisome
proliferator-activated receptor-gamma. J Clin Endocrinol Metab 92:1606-1612, 2007
101. Doney,AS, Fischer,B, Leese,G, Morris,AD, Palmer,CN: Cardiovascular risk in type 2
diabetes is associated with variation at the PPARG locus: a Go-DARTS study.
Arterioscler Thromb Vasc Biol 24:2403-2407, 2004
102. Barroso,I, Gurnell,M, Crowley,VE, Agostini,M, Schwabe,JW, Soos,MA, Maslen,GL,
Williams,TD, Lewis,H, Schafer,AJ, Chatterjee,VK, O'Rahilly,S: Dominant negative
mutations in human PPARgamma associated with severe insulin resistance, diabetes
mellitus and hypertension. Nature 402:880-883, 1999
103. Semple,RK, Chatterjee,VK, O'Rahilly,S: PPAR gamma and human metabolic disease. J
Clin Invest 116:581-589, 2006
104. Ihle,JN: Cytokine receptor signalling. Nature 377:591-594, 1995
105. Darnell,JE, Jr.: STATs and gene regulation. Science 277:1630-1635, 1997
106. Schindler,CW: Series introduction. JAK-STAT signaling in human disease. J Clin Invest
109:1133-1137, 2002
107. Pellegrini,S, Dusanter-Fourt,I: The structure, regulation and function of the Janus kinases
(JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem
248:615-633, 1997
108. Schindler,C, Darnell,JE, Jr.: Transcriptional responses to polypeptide ligands: the JAKSTAT pathway. Annu Rev Biochem 64:621-651, 1995
109. Liu,X, Robinson,GW, Gouilleux,F, Groner,B, Hennighausen,L: Cloning and expression
of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in
mouse mammary tissue. Proc Natl Acad Sci U S A 92:8831-8835, 1995
110. Teglund,S, McKay,C, Schuetz,E, van Deursen,JM, Stravopodis,D, Wang,D, Brown,M,
Bodner,S, Grosveld,G, Ihle,JN: Stat5a and Stat5b proteins have essential and
nonessential, or redundant, roles in cytokine responses. Cell 93:841-850, 1998

99

111. Moller,N, Jorgensen,JO, Moller,J, Orskov,L, Ovesen,P, Schmitz,O, Christiansen,JS,
Orskov,H: Metabolic effects of growth hormone in humans. Metabolism 44:33-36, 1995
112. Berryman,DE, List,EO, Coschigano,KT, Behar,K, Kim,JK, Kopchick,JJ: Comparing
adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF
Res 14:309-318, 2004
113. Olsson,B, Bohlooly,Y, Fitzgerald,SM, Frick,F, Ljungberg,A, Ahren,B, Tornell,J,
Bergstrom,G, Oscarsson,J: Bovine growth hormone transgenic mice are resistant to dietinduced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet.
Endocrinology 146:920-930, 2005
114. Dominici,FP, Hauck,S, Argentino,DP, Bartke,A, Turyn,D: Increased insulin sensitivity
and upregulation of insulin receptor, insulin receptor substrate (IRS)-1 and IRS-2 in liver
of Ames dwarf mice. J Endocrinol 173:81-94, 2002
115. Coschigano,KT, Holland,AN, Riders,ME, List,EO, Flyvbjerg,A, Kopchick,JJ: Deletion,
but not antagonism, of the mouse growth hormone receptor results in severely decreased
body weights, insulin, and insulin-like growth factor I levels and increased life span.
Endocrinology 144:3799-3810, 2003
116. Murray,RD, Adams,JE, Shalet,SM: Adults with partial growth hormone deficiency have
an adverse body composition. J Clin Endocrinol Metab 89:1586-1591, 2004
117. Beshyah,SA, Freemantle,C, Thomas,E, Rutherford,O, Page,B, Murphy,M, Johnston,DG:
Abnormal body composition and reduced bone mass in growth hormone deficient
hypopituitary adults. Clin Endocrinol (Oxf) 42:179-189, 1995
118. de Boer,H, Blok,GJ, Voerman,HJ, De Vries,PM, van der Veen,EA: Body composition in
adult growth hormone-deficient men, assessed by anthropometry and bioimpedance
analysis. J Clin Endocrinol Metab 75:833-837, 1992
119. Salomon,F, Cuneo,RC, Hesp,R, Sonksen,PH: The effects of treatment with recombinant
human growth hormone on body composition and metabolism in adults with growth
hormone deficiency. N Engl J Med 321:1797-1803, 1989
120. Bengtsson,BA, Abs,R, Bennmarker,H, Monson,JP, Feldt-Rasmussen,U, HernbergStahl,E, Westberg,B, Wilton,P, Wuster,C: The effects of treatment and the individual
responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults.
100

KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab
84:3929-3935, 1999
121. Beshyah,SA, Freemantle,C, Shahi,M, Anyaoku,V, Merson,S, Lynch,S, Skinner,E,
Sharp,P, Foale,R, Johnston,DG: Replacement treatment with biosynthetic human growth
hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 42:7384, 1995
122. Engelson,ES, Glesby,MJ, Mendez,D, Albu,JB, Wang,J, Heymsfield,SB, Kotler,DP:
Effect of recombinant human growth hormone in the treatment of visceral fat
accumulation in HIV infection. J Acquir Immune Defic Syndr 30:379-391, 2002
123. Vigano,A, Mora,S, Manzoni,P, Schneider,L, Beretta,S, Molinaro,M, di Natale,B,
Brambilla,P: Effects of recombinant growth hormone on visceral fat accumulation: pilot
study in human immunodeficiency virus-infected adolescents. J Clin Endocrinol Metab
90:4075-4080, 2005
124. Myers,SE, Carrel,AL, Whitman,BY, Allen,DB: Sustained benefit after 2 years of growth
hormone on body composition, fat utilization, physical strength and agility, and growth in
Prader-Willi syndrome. J Pediatr 137:42-49, 2000
125. Herrington,J, Smit,LS, Schwartz,J, Carter-Su,C: The role of STAT proteins in growth
hormone signaling. Oncogene 19:2585-2597, 2000
126. Waxman,DJ, O'Connor,C: Growth hormone regulation of sex-dependent liver gene
expression. Mol Endocrinol 20:2613-2629, 2006
127. Bole-Feysot,C, Goffin,V, Edery,M, Binart,N, Kelly,PA: Prolactin (PRL) and its receptor:
actions, signal transduction pathways and phenotypes observed in PRL receptor knockout
mice. Endocr Rev 19:225-268, 1998
128. Avruch,J, Zhang,XF, Kyriakis,JM: Raf meets Ras: completing the framework of a signal
transduction pathway. Trends Biochem Sci 19:279-283, 1994
129. Bailey,JP, Nieport,KM, Herbst,MP, Srivastava,S, Serra,RA, Horseman,ND: Prolactin and
transforming growth factor-beta signaling exert opposing effects on mammary gland
morphogenesis, involution, and the Akt-forkhead pathway. Mol Endocrinol 18:11711184, 2004
101

130. Kisseleva,T, Bhattacharya,S, Braunstein,J, Schindler,CW: Signaling through the
JAK/STAT pathway, recent advances and future challenges. Gene 285:1-24, 2002
131. Ling,C, Hellgren,G, Gebre-Medhin,M, Dillner,K, Wennbo,H, Carlsson,B, Billig,H:
Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during
lactation and in PRL-transgenic mice. Endocrinology 141:3564-3572, 2000
132. Ling,C, Svensson,L, Oden,B, Weijdegard,B, Eden,B, Eden,S, Billig,H: Identification of
functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase
activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804-1808, 2003
133. McAveney,KM, Gimble,JM, Yu-Lee,L: Prolactin receptor expression during adipocyte
differentiation of bone marrow stroma. Endocrinology 137:5723-5726, 1996
134. Nanbu-Wakao,R, Fujitani,Y, Masuho,Y, Muramatu,M, Wakao,H: Prolactin enhances
CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferatoractivated receptor gamma (PPAR gamma) messenger RNA expression and stimulates
adipogenic conversion of NIH-3T3 cells. Mol Endocrinol 14:307-316, 2000
135. Greenman,Y, Tordjman,K, Stern,N: Increased body weight associated with prolactin
secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin
Endocrinol (Oxf) 48:547-553, 1998
136. Fortun-Lamothe,L, Langin,D, Lafontan,M: Influence of prolactin on in vivo and in vitro
lipolysis in rabbits. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 115:141147, 1996
137. Fielder,PJ, Talamantes,F: The lipolytic effects of mouse placental lactogen II, mouse
prolactin, and mouse growth hormone on adipose tissue from virgin and pregnant mice.
Endocrinology 121:493-497, 1987
138. Flint,DJ, Clegg,RA, Vernon,RG: Prolactin and the regulation of adipose-tissue
metabolism during lactation in rats. Mol Cell Endocrinol 22:265-275, 1981
139. Stephens,JM, Morrison,RF, Pilch,PF: The expression and regulation of STATs during
3T3-L1 adipocyte differentiation. J Biol Chem 271:10441-10444, 1996

102

140. Harp,JB, Franklin,D, Vanderpuije,AA, Gimble,JM: Differential expression of signal
transducers and activators of transcription during human adipogenesis. Biochem Biophys
Res Commun 281:907-912, 2001
141. Stephens,JM, Morrison,RF, Wu,Z, Farmer,SR: PPARgamma ligand-dependent induction
of STAT1, STAT5A, and STAT5B during adipogenesis. Biochem Biophys Res Commun
262:216-222, 1999
142. Stewart,WC, Morrison,RF, Young,SL, Stephens,JM: Regulation of signal transducers
and activators of transcription (STATs) by effectors of adipogenesis: coordinate
regulation of STATs 1, 5A, and 5B with peroxisome proliferator-activated receptorgamma and C/AAAT enhancer binding protein-alpha. Biochim Biophys Acta 1452:188196, 1999
143. Yarwood,SJ, Sale,EM, Sale,GJ, Houslay,MD, Kilgour,E, Anderson,NG: Growth
hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus
kinase/signal transducer and activator of transcription but not mitogen-activated protein
kinase or p70 S6 kinase signaling. J Biol Chem 274:8662-8668, 1999
144. Shang,CA, Waters,MJ: Constitutively active signal transducer and activator of
transcription 5 can replace the requirement for growth hormone in adipogenesis of 3T3F442A preadipocytes. Mol Endocrinol 17:2494-2508, 2003
145. Nanbu-Wakao,R, Morikawa,Y, Matsumura,I, Masuho,Y, Muramatsu,MA, Senba,E,
Wakao,H: Stimulation of 3T3-L1 adipogenesis by signal transducer and activator of
transcription 5. Mol Endocrinol 16:1565-1576, 2002
146. Floyd,ZE, Stephens,JM: STAT5A promotes adipogenesis in nonprecursor cells and
associates with the glucocorticoid receptor during adipocyte differentiation. Diabetes
52:308-314, 2003
147. Fain,JN, Ihle,JH, Bahouth,SW: Stimulation of lipolysis but not of leptin release by
growth hormone is abolished in adipose tissue from Stat5a and b knockout mice.
Biochem Biophys Res Commun 263:201-205, 1999
148. Baugh,JE, Jr., Floyd,ZE, Stephens,JM: The modulation of STAT5A/GR complexes
during fat cell differentiation and in mature adipocytes. Obesity (Silver Spring) 15:583590, 2007

103

149. Kawai,M, Namba,N, Mushiake,S, Etani,Y, Nishimura,R, Makishima,M, Ozono,K:
Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the
Stat5A/5B-PPARgamma pathway. J Mol Endocrinol 38:19-34, 2007
150. Lefterova,MI, Lazar,MA: New developments in adipogenesis. Trends Endocrinol Metab
20:107-114, 2009
151. Coulter,AA, Stephens,JM: STAT5 activators modulate acyl CoA oxidase (AOX)
expression in adipocytes and STAT5A binds to the AOX promoter in vitro. Biochem
Biophys Res Commun 344:1342-1345, 2006
152. Richter,HE, Albrektsen,T, Billestrup,N: The role of signal transducer and activator of
transcription 5 in the inhibitory effects of GH on adipocyte differentiation. J Mol
Endocrinol 30:139-150, 2003
153. Hogan,JC, Stephens,JM: The regulation of fatty acid synthase by STAT5A. Diabetes
54:1968-1975, 2005
154. Balhoff,JP, Stephens,JM: Highly specific and quantitative activation of STATs in 3T3-L1
adipocytes. Biochem Biophys Res Commun 247:894-900, 1998
155. Pflanz,S, Hibbert,L, Mattson,J, Rosales,R, Vaisberg,E, Bazan,JF, Phillips,JH,
McClanahan,TK, de Waal,MR, Kastelein,RA: WSX-1 and glycoprotein 130 constitute a
signal-transducing receptor for IL-27. J Immunol 172:2225-2231, 2004
156. Derouet,D, Rousseau,F, Alfonsi,F, Froger,J, Hermann,J, Barbier,F, Perret,D, Diveu,C,
Guillet,C, Preisser,L, Dumont,A, Barbado,M, Morel,A, deLapeyriere,O, Gascan,H,
Chevalier,S: Neuropoietin, a new IL-6-related cytokine signaling through the ciliary
neurotrophic factor receptor. Proc Natl Acad Sci U S A 101:4827-4832, 2004
157. Heinrich,PC, Behrmann,I, Haan,S, Hermanns,HM, Muller-Newen,G, Schaper,F:
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J
374:1-20, 2003
158. Hilton,DJ, Hilton,AA, Raicevic,A, Rakar,S, Harrison-Smith,M, Gough,NM, Begley,CG,
Metcalf,D, Nicola,NA, Willson,TA: Cloning of a murine IL-11 receptor alpha-chain;
requirement for gp130 for high affinity binding and signal transduction. EMBO J
13:4765-4775, 1994
104

159. Robledo,O, Guillet,C, Chevalier,S, Fourcin,M, Froger,J, Pouplard-Barthelaix,A,
Pennica,D, Gascan,H: Hepatocyte-derived cell lines express a functional receptor for
cardiotrophin-1. Eur Cytokine Netw 8:245-252, 1997
160. Davis,S, Aldrich,TH, Stahl,N, Pan,L, Taga,T, Kishimoto,T, Ip,NY, Yancopoulos,GD:
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF
receptor. Science 260:1805-1808, 1993
161. Elson,GC, Lelievre,E, Guillet,C, Chevalier,S, Plun-Favreau,H, Froger,J, Suard,I, de
Coignac,AB, Delneste,Y, Bonnefoy,JY, Gauchat,JF, Gascan,H: CLF associates with
CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat
Neurosci 3:867-872, 2000
162. Febbraio,MA: gp130 receptor ligands as potential therapeutic targets for obesity. J Clin
Invest 117:841-849, 2007
163. Tenney,R, Stansfield,K, Pekala,PH: Interleukin 11 signaling in 3T3-L1 adipocytes. J Cell
Physiol 202:160-166, 2005
164. Stephens,JM, Lumpkin,SJ, Fishman,JB: Activation of signal transducers and activators of
transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma
in adipocytes. J Biol Chem 273:31408-31416, 1998
165. Zvonic,S, Cornelius,P, Stewart,WC, Mynatt,RL, Stephens,JM: The regulation and
activation of ciliary neurotrophic factor signaling proteins in adipocytes. J Biol Chem
278:2228-2235, 2003
166. Zvonic,S, Hogan,JC, rbour-Reily,P, Mynatt,RL, Stephens,JM: Effects of cardiotrophin on
adipocytes. J Biol Chem 279:47572-47579, 2004
167. White,UA, Stewart,WC, Mynatt,RL, Stephens,JM: Neuropoietin attenuates adipogenesis
and induces insulin resistance in adipocytes. J Biol Chem 283:22505-22512, 2008
168. Hogan,JC, Stephens,JM: Effects of leukemia inhibitory factor on 3T3-L1 adipocytes. J
Endocrinol 185:485-496, 2005
169. Zvonic,S, Baugh,JE, Jr., Arbour-Reily,P, Mynatt,RL, Stephens,JM: Cross-talk among
gp130 cytokines in adipocytes. J Biol Chem 280:33856-33863, 2005
105

170. White,UA, Coulter,AA, Miles,TK, Stephens,JM: The STAT5A-mediated induction of
pyruvate dehydrogenase kinase 4 expression by prolactin or growth hormone in
adipocytes. Diabetes 56:1623-1629, 2007
171. Schindler,C: Cytokines and JAK-STAT signaling. Exp Cell Res 253:7-14, 1999
172. Davidson,MB: Effect of growth hormone on carbohydrate and lipid metabolism. Endocr
Rev 8:115-131, 1987
173. Sugden,MC, Holness,MJ: Recent advances in mechanisms regulating glucose oxidation
at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol
Metab 284:E855-E862, 2003
174. Bowker-Kinley,MM, Davis,WI, Wu,P, Harris,RA, Popov,KM: Evidence for existence of
tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J
329 ( Pt 1):191-196, 1998
175. Sugden,MC, Bulmer,K, Augustine,D, Holness,MJ: Selective modification of pyruvate
dehydrogenase kinase isoform expression in rat pancreatic islets elicited by starvation
and activation of peroxisome proliferator-activated receptor-alpha: implications for
glucose-stimulated insulin secretion. Diabetes 50:2729-2736, 2001
176. Peters,SJ, Harris,RA, Wu,P, Pehleman,TL, Heigenhauser,GJ, Spriet,LL: Human skeletal
muscle PDH kinase activity and isoform expression during a 3-day high-fat/lowcarbohydrate diet. Am J Physiol Endocrinol Metab 281:E1151-E1158, 2001
177. Chen,G, Wang,L, Liu,S, Chuang,C, Roche,TE: Activated function of the pyruvate
dehydrogenase phosphatase through Ca2+-facilitated binding to the inner lipoyl domain
of the dihydrolipoyl acetyltransferase. J Biol Chem 271:28064-28070, 1996
178. Roche,TE, Baker,JC, Yan,X, Hiromasa,Y, Gong,X, Peng,T, Dong,J, Turkan,A,
Kasten,SA: Distinct regulatory properties of pyruvate dehydrogenase kinase and
phosphatase isoforms. Prog Nucleic Acid Res Mol Biol 70:33-75, 2001
179. Holness,MJ, Sugden,MC: Regulation of pyruvate dehydrogenase complex activity by
reversible phosphorylation. Biochem Soc Trans 31:1143-1151, 2003

106

180. Jeoung,NH, Wu,P, Joshi,MA, Jaskiewicz,J, Bock,CB, paoli-Roach,AA, Harris,RA: Role
of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during
starvation. Biochem J 397:417-425, 2006
181. Sugden,MC, Fryer,LG, Orfali,KA, Priestman,DA, Donald,E, Holness,MJ: Studies of the
long-term regulation of hepatic pyruvate dehydrogenase kinase. Biochem J 329 ( Pt
1):89-94, 1998
182. Holness,MJ, Kraus,A, Harris,RA, Sugden,MC: Targeted upregulation of pyruvate
dehydrogenase kinase (PDK)-4 in slow-twitch skeletal muscle underlies the stable
modification of the regulatory characteristics of PDK induced by high-fat feeding.
Diabetes 49:775-781, 2000
183. Majer,M, Popov,KM, Harris,RA, Bogardus,C, Prochazka,M: Insulin downregulates
pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to
increased lipid oxidation in insulin-resistant subjects. Mol Genet Metab 65:181-186, 1998
184. Lee,FN, Zhang,L, Zheng,D, Choi,WS, Youn,JH: Insulin suppresses PDK-4 expression in
skeletal muscle independently of plasma FFA. Am J Physiol Endocrinol Metab 287:E69E74, 2004
185. Huang,B, Wu,P, Bowker-Kinley,MM, Harris,RA: Regulation of pyruvate dehydrogenase
kinase expression by peroxisome proliferator-activated receptor-alpha ligands,
glucocorticoids, and insulin. Diabetes 51:276-283, 2002
186. Rosa,G, Di,RP, Manco,M, Greco,AV, Castagneto,M, Vidal,H, Mingrone,G: Reduced
PDK4 expression associates with increased insulin sensitivity in postobese patients. Obes
Res 11:176-182, 2003
187. Laemmli,UK: Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227:680-685, 1970
188. Ritzenthaler,JD, Goldstein,RH, Fine,A, Lichtler,A, Rowe,DW, Smith,BD: Transforminggrowth-factor-beta activation elements in the distal promoter regions of the rat alpha 1
type I collagen gene. Biochem J 280 ( Pt 1):157-162, 1991
189. Stephens,JM, Pekala,PH: Transcriptional repression of the GLUT4 and C/EBP genes in
3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 266:21839-21845, 1991
107

190. Ehret,GB, Reichenbach,P, Schindler,U, Horvath,CM, Fritz,S, Nabholz,M, Bucher,P:
DNA binding specificity of different STAT proteins. Comparison of in vitro specificity
with natural target sites. J Biol Chem 276:6675-6688, 2001
191. Groop,L, Segerlantz,M, Bramnert,M: Insulin sensitivity in adults with growth hormone
deficiency and effect of growth hormone treatment. Horm Res 64 Suppl 3:45-50, 2005
192. Zinger,M, McFarland,M, Ben-Jonathan,N: Prolactin expression and secretion by human
breast glandular and adipose tissue explants. J Clin Endocrinol Metab 88:689-696, 2003
193. Riddick,DH, Luciano,AA, Kusmik,WF, Maslar,IA: De novo synthesis of prolactin by
human decidua. Life Sci 23:1913-1921, 1978
194. Ben-Jonathan,N, Hugo,ER, Brandebourg,TD, LaPensee,CR: Focus on prolactin as a
metabolic hormone. Trends Endocrinol Metab 17:110-116, 2006
195. Hugo,ER, Brandebourg,TD, Comstock,CE, Gersin,KS, Sussman,JJ, Ben-Jonathan,N:
LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 147:306313, 2006
196. Asai-Sato,M, Okamoto,M, Endo,M, Yoshida,H, Murase,M, Ikeda,M, Sakakibara,H,
Takahashi,T, Hirahara,F: Hypoadiponectinemia in lean lactating women: Prolactin
inhibits adiponectin secretion from human adipocytes. Endocr J 53:555-562, 2006
197. Ling,C, Billig,H: PRL receptor-mediated effects in female mouse adipocytes: PRL
induces suppressors of cytokine signaling expression and suppresses insulin-induced
leptin production in adipocytes in vitro. Endocrinology 142:4880-4890, 2001
198. Ryan,EA, Enns,L: Role of gestational hormones in the induction of insulin resistance. J
Clin Endocrinol Metab 67:341-347, 1988
199. Schernthaner,G, Prager,R, Punzengruber,C, Luger,A: Severe hyperprolactinaemia is
associated with decreased insulin binding in vitro and insulin resistance in vivo.
Diabetologia 28:138-142, 1985
200. Flint,DJ, Knight,CH: Interactions of prolactin and growth hormone (GH) in the
regulation of mammary gland function and epithelial cell survival. J Mammary Gland
Biol Neoplasia 2:41-48, 1997
108

201. Furuyama,T, Kitayama,K, Yamashita,H, Mori,N: Forkhead transcription factor FOXO1
(FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy
deprivation. Biochem J 375:365-371, 2003
202. Kwon,HS, Huang,B, Unterman,TG, Harris,RA: Protein kinase B-alpha inhibits human
pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation
of FOXO transcription factors. Diabetes 53:899-910, 2004
203. Ma,K, Zhang,Y, Elam,MB, Cook,GA, Park,EA: Cloning of the rat pyruvate
dehydrogenase kinase 4 gene promoter: activation of pyruvate dehydrogenase kinase 4 by
the peroxisome proliferator-activated receptor gamma coactivator. J Biol Chem
280:29525-29532, 2005
204. Wende,AR, Huss,JM, Schaeffer,PJ, Giguere,V, Kelly,DP: PGC-1alpha coactivates PDK4
gene expression via the orphan nuclear receptor ERRalpha: a mechanism for
transcriptional control of muscle glucose metabolism. Mol Cell Biol 25:10684-10694,
2005
205. Mayers,RM, Leighton,B, Kilgour,E: PDH kinase inhibitors: a novel therapy for Type II
diabetes? Biochem Soc Trans 33:367-370, 2005
206. Flier,JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell
116:337-350, 2004
207. Taga,T, Hibi,M, Hirata,Y, Yamasaki,K, Yasukawa,K, Matsuda,T, Hirano,T,
Kishimoto,T: Interleukin-6 triggers the association of its receptor with a possible signal
transducer, gp130. Cell 58:573-581, 1989
208. Tartaglia,LA, Dembski,M, Weng,X, Deng,N, Culpepper,J, Devos,R, Richards,GJ,
Campfield,LA, Clark,FT, Deeds,J, Muir,C, Sanker,S, Moriarty,A, Moore,KJ, Smutko,JS,
Mays,GG, Wool,EA, Monroe,CA, Tepper,RI: Identification and expression cloning of a
leptin receptor, OB-R. Cell 83:1263-1271, 1995
209. Nakashima,K, Narazaki,M, Taga,T: Overlapping and distinct signals through leptin
receptor (OB-R) and a closely related cytokine signal transducer, gp130. FEBS Lett
401:49-52, 1997
210. Cohen,B, Novick,D, Rubinstein,M: Modulation of insulin activities by leptin. Science
274:1185-1188, 1996
109

211. Boulton,TG, Stahl,N, Yancopoulos,GD: Ciliary neurotrophic factor/leukemia inhibitory
factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of
a common set of proteins overlapping those induced by other cytokines and growth
factors. J Biol Chem 269:11648-11655, 1994
212. Cota,D, Barrera,JG, Seeley,RJ: Leptin in energy balance and reward: two faces of the
same coin? Neuron 51:678-680, 2006
213. Oh,H, Fujio,Y, Kunisada,K, Hirota,H, Matsui,H, Kishimoto,T, Yamauchi-Takihara,K:
Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein
kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 273:97039710, 1998
214. Watt,MJ, Dzamko,N, Thomas,WG, Rose-John,S, Ernst,M, Carling,D, Kemp,BE,
Febbraio,MA, Steinberg,GR: CNTF reverses obesity-induced insulin resistance by
activating skeletal muscle AMPK. Nat Med 12:541-548, 2006
215. Sleeman,MW, Anderson,KD, Lambert,PD, Yancopoulos,GD, Wiegand,SJ: The ciliary
neurotrophic factor and its receptor, CNTFR alpha. Pharm Acta Helv 74:265-272, 2000
216. Miller,RG, Petajan,JH, Bryan,WW, Armon,C, Barohn,RJ, Goodpasture,JC, Hoagland,RJ,
Parry,GJ, Ross,MA, Stromatt,SC: A placebo-controlled trial of recombinant human
ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS
Study Group. Ann Neurol 39:256-260, 1996
217. Gloaguen,I, Costa,P, Demartis,A, Lazzaro,D, Di,MA, Graziani,R, Paonessa,G, Chen,F,
Rosenblum,CI, Van der Ploeg,LH, Cortese,R, Ciliberto,G, Laufer,R: Ciliary neurotrophic
factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc
Natl Acad Sci U S A 94:6456-6461, 1997
218. Lambert,PD, Anderson,KD, Sleeman,MW, Wong,V, Tan,J, Hijarunguru,A, Corcoran,TL,
Murray,JD, Thabet,KE, Yancopoulos,GD, Wiegand,SJ: Ciliary neurotrophic factor
activates leptin-like pathways and reduces body fat, without cachexia or rebound weight
gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 98:4652-4657, 2001
219. Masu,Y, Wolf,E, Holtmann,B, Sendtner,M, Brem,G, Thoenen,H: Disruption of the
CNTF gene results in motor neuron degeneration. Nature 365:27-32, 1993

110

220. DeChiara,TM, Vejsada,R, Poueymirou,WT, Acheson,A, Suri,C, Conover,JC,
Friedman,B, McClain,J, Pan,L, Stahl,N, Ip,NY, Yancopoulos,GD: Mice lacking the
CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at
birth. Cell 83:313-322, 1995
221. Ceresa,BP, Pessin,JE: Insulin stimulates the serine phosphorylation of the signal
transducer and activator of transcription (STAT3) isoform. J Biol Chem 271:1212112124, 1996
222. Starr,R, Willson,TA, Viney,EM, Murray,LJ, Rayner,JR, Jenkins,BJ, Gonda,TJ,
Alexander,WS, Metcalf,D, Nicola,NA, Hilton,DJ: A family of cytokine-inducible
inhibitors of signalling. Nature 387:917-921, 1997
223. Miyaoka,Y, Tanaka,M, Naiki,T, Miyajima,A: Oncostatin M inhibits adipogenesis
through the RAS/ERK and STAT5 signaling pathways. J Biol Chem 281:37913-37920,
2006
224. Song,HY, Jeon,ES, Kim,JI, Jung,JS, Kim,JH: Oncostatin M promotes osteogenesis and
suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem
cells. J Cell Biochem 101:1238-1251, 2007
225. Smith,PJ, Wise,LS, Berkowitz,R, Wan,C, Rubin,CS: Insulin-like growth factor-I is an
essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 263:94029408, 1988
226. Bjorbaek,C, El-Haschimi,K, Frantz,JD, Flier,JS: The role of SOCS-3 in leptin signaling
and leptin resistance. J Biol Chem 274:30059-30065, 1999
227. Emanuelli,B, Peraldi,P, Filloux,C, Chavey,C, Freidinger,K, Hilton,DJ, Hotamisligil,GS,
Van,OE: SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor
necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944-47949,
2001
228. Bousquet,C, Susini,C, Melmed,S: Inhibitory roles for SHP-1 and SOCS-3 following
pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest
104:1277-1285, 1999

111

229. Magrangeas,F, Boisteau,O, Denis,S, Jacques,Y, Minvielle,S: Negative regulation of
onconstatin M signaling by suppressor of cytokine signaling (SOCS-3). Eur Cytokine
Netw 12:309-315, 2001
230. Auernhammer,CJ, Isele,NB, Kopp,FB, Spoettl,G, Cengic,N, Weber,MM, Senaldi,G,
Engelhardt,D: Novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like
cytokine) stimulates corticotroph function via a signal transducer and activator of
transcription-dependent mechanism negatively regulated by suppressor of cytokine
signaling-3. Endocrinology 144:1202-1210, 2003
231. Villarino,AV, Stumhofer,JS, Saris,CJ, Kastelein,RA, de Sauvage,FJ, Hunter,CA: IL-27
limits IL-2 production during Th1 differentiation. J Immunol 176:237-247, 2006
232. Emanuelli,B, Peraldi,P, Filloux,C, Sawka-Verhelle,D, Hilton,D, Van,OE: SOCS-3 is an
insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985-15991,
2000
233. Adams,TE, Hansen,JA, Starr,R, Nicola,NA, Hilton,DJ, Billestrup,N: Growth hormone
preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of
cytokine receptor signaling. J Biol Chem 273:1285-1287, 1998
234. Fasnacht,N, Muller,W: Conditional gp130 deficient mouse mutants. Semin Cell Dev Biol
19:379-384, 2008
235. Taga,T, Kishimoto,T: Gp130 and the interleukin-6 family of cytokines. Annu Rev
Immunol 15:797-819, 1997
236. Ichihara,M, Hara,T, Kim,H, Murate,T, Miyajima,A: Oncostatin M and leukemia
inhibitory factor do not use the same functional receptor in mice. Blood 90:165-173, 1997
237. Wolins,NE, Quaynor,BK, Skinner,JR, Tzekov,A, Park,C, Choi,K, Bickel,PE: OP9 mouse
stromal cells rapidly differentiate into adipocytes: characterization of a useful new model
of adipogenesis. J Lipid Res 47:450-460, 2006
238. Blanchard,F, Duplomb,L, Wang,Y, Robledo,O, Kinzie,E, Pitard,V, Godard,A, Jacques,Y,
Baumann,H: Stimulation of leukemia inhibitory factor receptor degradation by
extracellular signal-regulated kinase. J Biol Chem 275:28793-28801, 2000

112

239. Blanchard,F, Wang,Y, Kinzie,E, Duplomb,L, Godard,A, Baumann,H: Oncostatin M
regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha,
and oncostatin M receptor beta by distinct mechanisms. J Biol Chem 276:47038-47045,
2001
240. Natal,C, Fortuno,MA, Restituto,P, Bazan,A, Colina,I, Diez,J, Varo,N: Cardiotrophin-1 is
expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol
Endocrinol Metab 294:E52-E60, 2008

113

APPENDIX
COPYRIGHT RELEASE PERMISSIONS
Copyright release for Chapter 2
http://diabetes.diabetesjournals.org/site/misc/ifora.xhtml
Copyright Assignment
The American Diabetes Association (ADA) holds the copyright on all material appearing in
Diabetes. All authors must check the appropriate boxes and sign the manuscript submission
form, which transfers copyright to the ADA in accordance with the Copyright Revision Act of
1976.
Reuse and Post-Prints
ADA's manuscript submission form addresses permission policies related to reuse and postprints. Please see below for the statement of provenance and other conditions:
Reuse. Authors are permitted to reuse portions of their ADA-copyrighted work, including tables
and figures, in their own work, and to reuse portions or all of their ADA-copyrighted work for
educational purposes, without submitting a request to ADA, provided that the proper citation and
copyright information is given.

114

Copyright release for Chapter 3
COPYRIGHT PERMISSION POLICY
http://www.jbc.org/home/about/permissions.dtl
For ASBMB Publications:
Journal of Biological Chemistry
Molecular and Cellular Proteomics
Journal of Lipid Research
ASBMB Today
For Non-Commercial uses:
NO FEE --NO PERMISSION NEEDED
You are free to copy, distribute, transmit and to adapt the work under the following
conditions:
Attribution. You must attribute the work in the manner specified by the original source
Noncommercial. You may not use the work for commercial purposes; including original
authors reusing content by a commercial publisher.

115

VITA
Ursula Antoinette White was born in October 1982, in Monroe, Louisiana, to Isaac and
Sarah White. Ursula grew up in Monroe, Louisiana, and attended Shady Grove Elementary
School. She graduated as Valedictorian from Ouachita Parish High School in 2000.

Ursula

began her undergraduate career in the fall of 2000 at Louisiana State University, where she
majored in biological sciences. In the spring of 2004, Ursula graduated with her Bachelor of
Science from Louisiana State University. She entered the graduate program at Louisiana State
University in the Department of Biological Sciences in the spring of 2005 as a doctoral student
under the mentoring of Dr. Jacqueline Stephens. Ursula will graduate with her Doctor of
Philosophy degree in biological sciences on August 7, 2009.

116

